In and Out of the Hospital, Neurohospitalists Shift Course… : Neurology Today – LWW Journals

Article In Brief

Neurologists who work in hospital settings discuss the changes their institutions have made to address the surge in COVID-19 patients.

When a longtime patient developed worrisome neurological symptoms in March, W. David Freeman, MD, FAAN, a neurointensivist at Mayo Clinic in Jacksonville, FL, interfaced with him via telemedicine. The virtual visit averted a trip to a hospital emergency room teeming with potentially contagious patients during the COVID-19 pandemic.

Dr. Freeman's patient, who had had a brain aneurysm before age 40 several years ago, had slurred speech and numbness and weakness on one side of his body. To arrange a virtual consultation, Mayo Clinic's Connected care team guided the patient, a former Florida resident who now lives in another state, in how to access telehealth software on his home computer and connect with Dr. Freeman.

With those symptoms, first, we're always thinking about transient ischemic attack, a precursor to a severe stroke, said Dr. Freeman, professor of neurology and neurosurgery at Mayo Clinic, where he is medical director of the neurosciences intensive care unit. Seizure can be another mimic.

Before the virtual visit, symptoms had resolved, Dr. Freeman advised the patient to check in via telemedicine as needed and to schedule an in-person visit a few months later.

On the hospital side, Dr. Freeman was one of the first physicians at Mayo Clinic in Flordia to use a telemedicine robot positioned in the emergency department to examine acute stroke patients remotely for administration of intravenous recombinant tissue plasminogen activators.

Nowadays, these telepresense robots can be equipped with a stethoscope and ultrasound port, which may enable a nurse, respiratory therapist, and physician to listen to the lungs from another location.

Such a telemedicine robot enabled Lelie V. Simon, DO, an emergency medicine physician and department chair, to develop a process that led to the first virtual diagnosis of COVID-19 at the Jacksonville Mayo Clinic, with minimal use of personal protective equipment and exposure to staff, Dr. Freeman said.

Respiratory distress can be seen on observation by using the visual camera on the telemedicine robot if a patient is breathing heavily or in distress, without the stethoscope, Dr. Freeman explained. However, he said, not all patients can be examined this way, if they are uncooperative or already on a breathing tube and require a proxy examiner such as a nurse in personal protective equipment.

COVID-19 has also forced us to rethink and consolidate nursing and medical staff trips into an admitted patient's room, he noted, administering medications every four to eight hours, if possible, instead of spacing them out every one to two hours.

As the coronavirus pandemic continues to strain the resources of health care systems across the country, neurologists are turning to telemedicine to triage patients remotely. With sophisticated technologies, they can replicate much of a traditional doctor's visit by observing and communicating with patients without risking a life-threatening infection.

Limiting the number of in-person interactions by using telemedicine and other methods also preserves the limited supply of personal protective equipment for front-line workers and enables them to carry out their job duties as safely as possible.

We're in a crisis, said Jana Wold, MD, associate professor of neurology and director of the Veterans' Affairs stroke program at the University of Utah Clinical Neurosciences Center in Salt Lake City. We're trying to keep our workforce well and as minimally exposed as possible. Otherwise, we won't have a workforce.

Despite having to expend additional time and effort setting up the camera and other equipment for telemedicine, nurses and other staff recognize that these are unique and unprecedented times, added Dr. Wold, who is also director of the adult neurology residency program. Health care workers are fully aware that this is the time to be innovative and to use technology in ways that we haven't before.

Telemedicine isn't a new phenomenon for many academic medical centers, including the University of Utah School of Medicine, which operates a broad telestroke network with 27 sites in the traditional hub-spoke model.

But this is a first for us to use it in our own emergency department, as we would normally just see these patients in person, she said.

At New York-Presbyterian/Weill Cornell Medical College, situated at the epicenter of the US coronavirus outbreak, most neurologists with outpatient office hours have converted those appointments to telemedicine visits, said Louise M. Klebanoff, MD, vice chair of clinical operations in the department of neurology.

In her experience, video-based visits are more suited for established patients. She is more comfortable using telemedicine for patients she previously examined and found to be stable with a baseline abnormality.

For new patients, however, those types of visits are not as straightforward for Dr. Klebanoff, a general neurologist who welcomes diagnostic challenges that present with the management of headaches and migraines, neck and back pain, pinched nerves, dizziness, and vertigo.

Without actually examining the patient, it is really difficult to do the type of evaluation I need to do, she said. When assessing a patient for dizziness, the physical examination allows me to determine if they have low blood pressure causing light-headedness, trouble walking, or benign positional vertigo.

For truly urgent medical needs, Dr. Klebanoff said, patients should still visit the hospital emergency room. A coronavirus isolation protocol has been instituted at New York-Presbyterian/Weill Cornell Medical College.

At this time, our ED is separating COVID-19 patients from non-COVID patients, she said. We have assigned attending physicians who are usually doing outpatient appointments to rotate through the ED to care for these patients.

At least one attending physician in every subspecialty is available for telephone consultations on an as-needed basis. Patient assessments in the emergency department will be followed with office appointments once that becomes a possibility. Hospitalists, as well as attending physicians specializing in stroke and critical care, are working as part of inpatient teams treating COVID-19 patients, Dr. Klebanoff said.

The mounting difficulties facing neurology peers on the country's east coast are on the mind of S. Andrew Josephson, MD, FAAN, professor and chair of neurology at the University of California, San Francisco.

As a neurohospitalist, Dr. Josephson is preparing for a large surge in his region, just in case, by planning and changing workflows to be a step ahead of the acceleration in growth of coronavirus cases.

On the outpatient side, providers are conducting very few in-person visits, except for the most urgent cases. We are almost purely telehealth at this point, Dr. Josephson said.

He noted that a shelter-in-place order in San Francisco, coupled with many patients watching young children at home during school closures, have made virtual visits much more convenient for faculty, staff, and patients while also halting spread of the virus.

Around hospitalized patients, clinical teams are more conscious than ever of the need to wear personal protective equipment while tending to those who have endured a stroke, complications from epilepsy, and other neurological emergencies during the pandemic. Amid a widespread US shortage of masks and gowns, Dr. Josephson said, one clinician is typically tasked with performing a hands-on patient exam in a room of the intensive care unit while other providers observe through a glass window.

In addition, within the hospital, we have expanded our ability to do video visits, he added.

Only one provider may be in the room with a patient, but the rest of them, including trainees, and a multidisciplinary teamfor instance, a respiratory therapist, social worker, and chaplaincould be beaming in via telemedicine to participate in the visit. This approach saves the available personal protective equipment for first responders directly seeing patients while also preventing the virus from infecting patients and staff, Dr. Josephson said.

For the very few patients seated in outpatient waiting rooms, the medical center is helping them maintain social distancing by rearranging chairs far apart and cleaning the areas more frequently. Even before patients and employees enter, Dr. Josephson said, they must answer questions about symptoms potentially suspicious for coronavirus, such as fever and cough. Those with symptoms are directed to respiratory screening clinics to determine whether they need to undergo further testing.

Conducting departmental meetings virtually from his office, he has been able to interact with his colleagues remotely, most of whom are working from home.

We also want to make sure that we're preserving our workforce, he said, foreseeing backup plans to substitute for faculty and residents who may become ill.

At EvergreenHealth Neuroscience Institute and Medicine Hospitalists in Kirkland, Washington, care coordination has ramped up since the first US cases of coronavirus were confirmed at its facility on February 28, said David Likosky, MD, FAAN, executive medical director of the EvergreenHealth Neuroscience Institute.

Close collaboration with various area hospitals, the health department, and other governmental agencies has helped plan the allocation of resources to where they are most in demand. No one hospital can do it all alone without reliance on others in a public health emergency of this magnitude, said Dr. Likosky, who is also director of stroke and neurohospitalist programs.

Within the hospital setting, pulmonary critical care specialists may align with neurohospitalists in taking care of an individual who has suffered a stroke. You can see how this cascades out in a tier fashion to meet the needs of our patients, Dr. Likosky said. So far, he added, Evergreen Health has had enough ventilators to serve patients, as well as a sufficient supply of nurses, with some volunteering to work additional shifts.

For surge planning in the hospital setting, neurointensivists help back up pulmonary critical care specialists; neurohospitalist back up the neurointensivists, and clinic neurologists (who may have lighter schedules) back up the neurohospitalists.

You can see how this cascades out in a tiered fashion to meet the needs of our patients, Dr. Likosky said. So far, he added, EvergreenHealthalong with Washington state's aggressive and early social distancing and cancellation of elective surgeries and visitshas flattened the resources needed curve enough that, while there has been a significant strain, patients have not gone without ventilators or appropriate nursing care.

At Cleveland Clinic, telemedicine visits have also become the norm during the pandemic for evaluating neurological conditions and titrating medications for previously examined patients. In addition, there are ongoing preparations for the possibility that neurologists may need to help with the shortage of providers to care for critically ill patients, said Marisa McGinley, DO, a neurologist and assistant professor of medicine in the Cleveland Clinic Lerner College of Medicine.

The current plan for redeployment would be for neurologists to aid with caring for non-ICU patients, Dr. McGinley said. In order to prepare neurologists for these types of duties, educational sessions are being designed to provide useful information about potential situations they may encounter.

Read the rest here:
In and Out of the Hospital, Neurohospitalists Shift Course... : Neurology Today - LWW Journals

AAN: Updated Practice Recommendations on PFO and Secondary Stroke Prevention – Neurology Advisor

The guideline subcommittee of the American Academy of Neurology (AAN) has updated practice recommendations on secondary stroke prevention and the management of patients with patent foramen ovale (PFO). The update was published in Neurology.

Current Evidence as the Basis for Recommendations

The guideline served as an update to the AANs practice advisory released in 2016, which provided clinical practice recommendations for secondary stroke prevention in patients with PFO. The AAN guideline subcommittee comprised a team of neurologists, internists, and cardiologists with experience and expertise in stroke and PFO. A systematic literature review was performed to identify new evidence that answered 2 key clinical questions.

The first question pertained to the role of percutaneous PFO closure in reducing stroke recurrence risk vs medical therapy only in patients with PFO who have had an otherwise cryptogenic ischemic stroke. The second question pertained to the role of anticoagulation in reducing stroke recurrence risk compared with antiplatelet therapy in this same patient population.

Based on current evidence, the guideline subcommittee suggests that percutaneous PFO closure likely reduces stroke recurrence in patients with cryptogenic stroke and PFO. The AAN subcommittee states that anticoagulation and antiplatelet medications could be equally effective in reducing recurrent stroke in these patients, according to available evidence.

Recommendation 1 Statements

In their first clinical recommendation statement, the AAN wrote that clinicians should thoroughly evaluate of patients who are being considered for PFO closure. This evaluation would help rule out alternative stroke mechanisms. The subcommittee also recommends that clinicians perform brain imaging to confirm stroke size, distribution, and the potential presence of either an embolic pattern or lacunar infarct. Complete vascular imaging should also be obtained in patients who are being considered for PFO closure. The ANN notes that vascular imaging, either MR angiography or CT angiography, should be performed on the cervical and intracranial vessels to identify dissection, atherosclerosis, or vasculopathy.

The subcommittee also recommends prolonged cardiac monitoring for 28 days or longer in patients being considered for PFO closure and who may be at risk of atrial fibrillation (AF). A baseline ECG can be used to screen for AF in these patients. A clinician who is experienced in treating stroke should perform a complete examination of the patient prior to PFO closure to ensure that PFO is the most plausible stroke mechanism. Clinicians should recommend against PFO closure if a higher-risk alternative stroke mechanism is identified.

Additionally, the guideline recommends that clinicians should assess for cardioembolic sources with transthoracic echocardiography and transesophageal echocardiography (TEE) assessment. The use of TEE would be appropriate if the first study fails to identify a high-risk stroke mechanism.

Recommendation 2 Statements

In their second series of recommendation statements, the AAN provided practice suggestions for patients over 60 years of age. The guideline states that a closure is recommended for patients in this age group who have a PFO and an embolic-appearing infarct with no other identified stroke mechanism, as long as the clinician discusses the potential benefits of the procedure. The guideline also recommends offering PFO closure in other populations, including patients between the ages of 60 to 65 years who have very few traditional vascular risk factors and no other identified stroke mechanism.

Younger patients, including those less than 30 years of age, can also receive PFO closure under the guideline recommendations if they have: a single, small; deep stroke less than 1.5 cm; a large shunt; and no evidence of vascular risk factors that would cause intrinsic small-vessel disease. The subcommittee also recommended a shared decision-making approach between patients and clinicians.

Recommendation 3 Statements

In the third series of statements, the AAN recommends the use of either antiplatelet medications or anticoagulation therapy in patients who choose to take medical therapy alone instead of PFO closure. For patients who are good candidates for PFO closure and require long-term anticoagulation because of either proven or suspected hypercoagulability, the AAN recommends that physicians counsel the patient on how the efficacy of closure and anticoagulation cannot be confirmed or discredited.

Call for Future Research

In their guideline, the AAN subcommittee wrote that additional research, including long-term and large-scale safety registries for patients who have received PFO closure are needed to assess the risk of device erosion, fracture, embolization, and thrombotic and endocarditis risks and the effect of residual shunts and incidence of AF.

Reference

Mess SR, Gronseth GS, Kent DM, et al. Practice advisory update summary: Patent foramen ovale and secondary stroke prevention: Report of the guideline subcommittee of the American Academy of Neurology [published online April 29, 2020]. Neurology. doi: 10.1212/WNL.0000000000009443

Read the rest here:
AAN: Updated Practice Recommendations on PFO and Secondary Stroke Prevention - Neurology Advisor

Pitt Researcher Studying Link Between COVID-19 And Stroke – 90.5 WESA

A University of Pittsburgh physician is leading an international effort to learn more about the link between COVID-19 and neurological symptoms, including stroke.

Dr. Sherry Chou, an associate professor of critical care medicine, neurology and neurosurgery, said reports have come in from all over the world that some COVID-19 patients are suffering strokes.

In some cases, people are reporting that folks are coming in primarily with a neurological disorder, and then later on, because of some degree of suspicion, they tested them for COVID and found them to be positive, Chou said. Of course, as a medical community, we're both interested and concerned.

Last week,the New England Journal of Medicine published a reportsummarizing the cases of five patients at Mt. Sinai Health System in New York City. All were under 50 years old, tested positive for COVID-19 and suffered large-vessel strokes within the same two-week period.

At least one Allegheny Health Network patient died after a COVID-related stroke. Sixty-four-year-old Mark Ramutis was riding out his symptoms at home when he awoke one morning unable to speak. At Allegheny General Hospital, a brain scan showed multiple clots and swelling in his brain. He died two days later.

What we have is sort of a fragmented picture where there are some examples of very young people without risk factors having stroke, said Dr. Ashis Tayal, a neurologist who directs stroke services at AHN. There are other examples of older adults with risk factors, also having severe forms of COVID, so it's difficult to reconcile those easily at this point."

Chou and her co-authors are seeking to determinewhether COVID-19 is a cause of stroke and other neurological symptoms, and if so, by what mechanism. She said it is unclear whether the novel coronavirus itself is causing the blood clots that are leading to strokes, or if the strokes are a secondary result of multiple organ failure among very sick patients.

The cases of the five Mt. Sinai patients complicate the latter theory, because their COVID-19 symptoms were not particularly severe. However, Chou cautioned that in areas such as New York City, where the virus has become endemic, it is possible that the fact that these patients had both strokes and COVID-19 could be coincidental.

My gut feeling will be theyre probably related, and thats what everybody's gut feeling is saying, Chou said. But as medical professionals and scientists, a gut feeling is not good enough.

More than 70 sites in 17 countries have registered through theNeurocritical Care Society websiteto collect patient data. Its difficult to launch a new study during a pandemic, said Chou, and the contagiousness of the novel coronavirus makes it particularly challenging. That means, for now, theyre focusing on the most basic data that providers are already collecting at patients bedsides, including age, symptom severity, underlying conditions, the results of basic blood tests and general neurological function. In later phases of the study, Chou and her colleagues hope to collect data from more advanced diagnostic tests, such as MRIs.

Its not clear how prevalent stroke and other neurological symptoms are in Covid-19 patients; thats one of the primary questions driving Chous research.

In order to know prevalence, we need to know how many people out there [have been infected with COVID-19], and from that we figure out what percentage or proportion of that population have this problem, Chou said. Because of the limited testing we still have we don't really know how much COVID there is in the community.

Chou expects the first results from the study to be available in late summer.

WESA receives funding from the University of Pittsburgh.

Continue reading here:
Pitt Researcher Studying Link Between COVID-19 And Stroke - 90.5 WESA

Study Illuminates the Role of Mitochondria in Neurodegeneration – UPMC

Share this on:

Researchers at the University of Pittsburgh have found a way to observe how misbehaving mitochondria can lead to neurological problems resembling neurodegenerative diseases in humans.

The study, publishedrecently in eLife,uses genetically-modified zebrafish larvae, whose see-through bodies give researchers a chance to watch whats happening inside their nervous system when mitochondria break down, such as during Parkinsons, Alzheimers, Huntingtons and chronic traumatic encephalopathy (CTE).

Edward Burton, M.D., Ph.D., associate professor of neurology at Pitt, UPMC Endowed Chair of Movement Disorders and neurologist at UPMC, and colleagues caused mitochondrial damage in specific compartments of zebrafish neurons, using technology developed by Marcel Bruchez, Ph.D., at Carnegie Mellon University.

Normal mitochondria (left, green) and light-damaged mitochondria (right)

Burton and colleaguesgenetically-modified zebrafish to express a protein called dL5 in the mitochondria of their neurons. The dL5 protein acts as a receptor that binds fluorescent molecules, which emit harmful oxygen molecules when exposed to red light, causing oxidative damage to the mitochondria.

The really big first here is that weve got a way of targeting a one micrometer component of specific cells in a whole animal, with absolute precision in terms of where and when the damage happens and how much damage there is, Burton said. Compare that to coarser techniques, such as adding chemicals to the zebrafishs water theres no way to control which cells get damaged.

Zebrafish with damaged mitochondria in their nervous systems (left) dont move around like normal zebrafish (right).

The researchers found that zebrafish with damaged mitochondria in their nervous system had no motor responses to stimulation. The mitochondria of affected zebrafish were swollen, losing many of their signature folds, in which ATP production the main energy units used by cells takes place. Without ATP, the neurons lost their membrane stability and started to die about a day after the initial light-evoked damage.

Zebrafish and human brains share many of the same structures and neuronal populations affected in neurodegeneration, such as dopamine-producing neurons that die in Parkinsons disease. By causing damage to the mitochondria of living zebrafish and observing what happened next, Burton and his team were able to glean insights into what might happen in humans with damaged mitochondria.

I look after Parkinsons disease patients clinically at UPMC, and from a clinicians point of view its very frustrating because we can only treat their symptoms, Burton said. We know they have damaged mitochondria. What I really need is a treatment that targets downstream events, to prevent the pathogenic cascade and arrest or slow the progression of clinical symptoms.

Burton and his lab have now restricted the expression of dL5 to only dopaminergic neurons in the brains of their zebrafish. Over the next one to two years, they expect to create a timeline of the biochemical events underlying cell death that mimics the one found in human patients.

Continued here:
Study Illuminates the Role of Mitochondria in Neurodegeneration - UPMC

Potential Impact of COVID-19 on Neurology Software Market Overview By New Technology, Demand And Scope 2020 To 2026 – Cole of Duty

The research report offers a comprehensive Coronavirus COVID-19 impact analysis of the Global Neurology Software Market, emphasizing on the key factors impacting the growth of the market. The factors affecting the growth of the market have been studied thoroughly and valuation of the market has been provided in the report. This report provides accurate information about various aspects, such as production chain, manufacturing capacity, and industry policies impacting the Global Neurology Software Market It analyzes the competitive landscape of this market and examined geographical distribution at length.

The recent developments in the market have also been taken into consideration while estimating the markets future scenario. This allows readers and market participants in forming efficient market strategies. Moreover, profiles of some of the leading players operating in the Global Neurology Software Market are profiled, including a detailed SWOT analysis that projects an overview of the potential growth trajectory of the market players in the coming years. It also discusses product portfolio, business segmentation, revenue, and financial overview of the leading players.

Get Free Sample PDF (Including Full TOC, Tables And Figures) of Market @ https://www.researchmoz.us/enquiry.php?type=S&repid=2649566

This report covers leading companies associated in Neurology Software market:

Scope of Neurology Software Market:The global Neurology Software market is valued at million US$ in 2017 and will reach million US$ by the end of 2025, growing at a CAGR of during 2018-2025.

This Market Report includesdrivers and restraints of the global Neurology Software market and their impact on each region during the forecast period. The report also comprises the study of current issues with consumers and opportunities. It also includes value chain analysis.

On the basis on the end users/applications,this report focuses on the status and outlook for major applications/end users, sales volume, Neurology Software market share and growth rate of Neurology Software foreach application, including-

On the basis of product,this report displays the sales volume, revenue (Million USD), product price, Neurology Software market share and growth rate ofeach type, primarily split into-

Enquiry For Discount or to Get Customized Report: https://www.researchmoz.us/enquiry.php?type=E&repid=2649566

Neurology Software Market: Regional analysis includes:

Neurology Software Market Report Structure at a Glance:

For More Information Kindly Contact: ResearchMozMr. Rohit Bhisey,90 State Street,Albany NY,United States 12207Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email: [emailprotected]Follow us on LinkedIn @ http://bit.ly/1TBmnVGMedia Release: https://www.researchmoz.us/pressreleaseFollow me on : http://marketresearchlatestreports.blogspot.com/

View post:
Potential Impact of COVID-19 on Neurology Software Market Overview By New Technology, Demand And Scope 2020 To 2026 - Cole of Duty

Neurologists Dust Off Their Stethoscopes, Join COVID Frontlines – MedicineNet

MAY 03, 2020 --Daniella Sisniega, MD, a neurology resident at Mt. Sinai Medical Center in New York City, recently dusted off her stethoscope and headed for the frontlines of the COVID-19 pandemic.

She announced her intentions on twitter, saying she is happy to do her part.

Sisniega joins other neurology attendings, fellows, and residents across the globe who are joining the ranks of their critical care and emergency medicine colleagues to provide them with much-needed back up.

Sisniega had always planned to volunteer in some way. Then she learned from her program director that the ED at Elmhurst Hospital in Queens, New York, was understaffed and needed extra hands. She signed up.

"I am currently working on the side of the emergency department that sees the COVID patients that do not require NIPPV [nasal intermittent positive pressure ventilation] or intubation," she told Medscape Medical News.

"As a resident, I see and staff new patients, but if needed I also check all patient oxygen saturations, make sure to titrate oxygen supplementation, refill oxygen tanks or whatever else is needed. It's all-hands-on-deck."

Emergency care differs from neurology in multiple ways, Sisniega said. COVID-19 patients require acute treatment, a contrast to the long-term, follow-up care required by neurology patients.

"To say the least, working in the ED in the middle of a pandemic is very different from a normal day in neurology, but it makes me appreciate what my ED colleagues do."

Sisniega also worked with an ophthalmologist and two volunteer physician assistants to come up with an innovative solution when the hospital temporarily ran out of a type of essential mask, a success she also shared on Twitter:

A Global Effort

Sisniega is not the only one redeploying during the pandemic. Physicians from across the globe are stepping up to help. Tim Wilkinson, MD, a neurology resident in Edinburgh, Scotland, also saw the need and acted:

"It's still early days, but I've been enjoying the switch. It was daunting at first, but the respiratory team were very welcoming, and it didn't take me long to find my feet. I'd like to think they have accepted me as one of their own," Wilkinson told Medscape Medical News.

Wilkinson recommends that neurologists looking to join multidisciplinary COVID-19 efforts should review the acute patient management and best practices for prescribing palliative care. "These are the two main aspects of working on a COVID-19 ward," he said.

Neurologists in northern Italy, the epicenter of the COVID-19 outbreak in Europe, have also left their usual posts to help during the pandemic.

Anna Bersano, MD, PhD, at the cerebrovascular unit at Fondazione Istituto Neurologico Carlo Besta in Milan, told Medscape Medical News that many of her colleagues have redeployed to teams at other facilities, especially in Bergamo and Brescia.

"Other neurologists at bigger hospitals were reallocated to emergency wards or internal medicine wards," she said.

Although Bersano was willing to help out, she contracted the virus at the end of February. "I was not redeployed. I was fortunate enough only to have a long fever, muscle pain, and ageusia. Now I'm recovering," she said.

Neurosurgeons have also answered the call to help, especially those who find they have more time on their hands because of the large volume of canceled elective surgeries at their institutions.

"We are supporting the frontlines as we can, deploying to emergency room and ICU where we can be helpful," Martina Stippler, MD, a neurosurgeon at Beth Israel Deaconess Medical Center, Boston, Massachusetts, told Medscape Medical News.

Waiting in the Wings

The intensity of COVID-19 outbreaks in different regions varies widely, but neurologists are ready and willing to switch specialties should the local infection rate and caseload spike.

"There has definitely been an effect of COVID. While we have not experienced a surge, the hospital has a steady influx of COVID patients," said Shyam Prabhakaran, MD, professor and chair of neurology at the University of Chicago Biological Sciences, Illinois.

Neurologists remain ready to redeploy as needed. Not content to wait, some neurology faculty are volunteering for shifts in the ED to help triage patients for admission, he added.

"The ED faces staff shortages in dealing with the increase in patients with ILI [influenza-like illness]."

The pandemic has also changed the number of people coming to his institution for stroke care, Prabhakaran added.

"Stroke admissions and EMS transports are down compared to pre-COVID," he lamented. "This indirect public health aspect of the pandemic is a major concern as we fear stroke patients are delaying care or staying home altogether."

The faculty and trainees in the neurology department at the University of Miami School of Medicine have not yet had to redeploy either, Ralph Sacco, MD, chief of neurology, told Medscape Medical News. "We may be faced with this when we see a Florida surge in the future."

It's the same scenario in Seattle. David Tirschwell, MD, professor of neurology and medical director of Comprehensive Stroke Care, University of Washington, said his hospital, Harborview Medical Center, "did incredible planning" for COVID-19 but, so far, there's been no surge in cases.

He praised King County in Washington State for "a remarkable job at flattening the curve."

For this reason, he and other neurologists have not had to redeploy.

"We're right about at our peak hospital usage, and we have not filled our ICU beds with these patients," he noted. "We had a multistep plan we never had to fully implement because the massive surge like we're hearing about in NYC just hasn't materialized here."

"Be Kind"

Back in NYC, Sisniega said the diverse backgrounds and expertise of her new team members surprised her.

"We have volunteers from all specialties including dermatology, psychiatry, ophthalmology, and of course from all areas of the country," she said.

"No matter what their previous roles were attending, RN, resident everyone is ready to contribute in whatever way is necessary," she added. "Just today I met an ophthalmology attending whose role was to keep stock of the number of ventilators in the building."

Sisniega's neurology skills have come in handy. "As neurology residents we often respond to stroke codes and we're comfortable with sick patients whose medical history we're not familiar with," she said.

Neurologists are accustomed to acting quickly when patients suddenly decompensate. "Unfortunately, COVID patients can also decompensate unexpectedly," Sisniega said.

Her words of advice for other neurologists considering redeployment to help with COVID-19: "The patients are very scared and anxious. Be kind. You may be the only conversation they had that day."

References

2020 WebMD, LLC. All Rights Reserved.

See the original post:
Neurologists Dust Off Their Stethoscopes, Join COVID Frontlines - MedicineNet

Stroke prevention during the pandemic – The Irish Times

Sir, Amidst the appropriate, radical and urgent restructuring of our healthcare services in Ireland and internationally to deal with the global Covid-19 pandemic, it is also essential that patients with other urgent high-risk conditions are diagnosed, investigated and treated urgently.

Stroke is the most common cause of acquired physical disability and the second or third most common cause of death in adults in middle-high income countries. Most strokes are due to reduced blood supply to the brain and are called ischaemic strokes.

Some are preceded by a transient ischaemic attack (TIA), which is sometimes referred to as a warning stroke by patients, and this provides patients and doctors with an extremely important window of opportunity for urgent stroke prevention.

Symptoms last for less than 24 hours with a TIA (usually minutes) and for 24 hours with a stroke, but the symptoms are the same. TIAs cause the S symptoms: sight (blurring or loss of vision or double vision); speech (impaired expression, understanding or slurring); swallowing (less common than with stroke); strength (weakness of the face, arm and/or leg), sensation (usually numbness or reduced sensation and less commonly pins and needles on the face, arm and/or leg), or stability (sudden unsteadiness or a sensation of movement called vertigo).

In addition to our other work at Tallaght University Hospital, we continue to run a daily one-stop rapid access stroke prevention (Rasp) service which is co-ordinated by the vascular neurology and age-related healthcare and stroke medicine consultants on alternate weeks, in close collaboration with our colleagues in vascular surgery, cardiology, phlebotomy, medical administration and radiology.

We accept email referrals from our local GPs, emergency department physicians and hospital consultant colleagues via our local e-referral pathway, with a view to assessing all patients with suspected TIAs within 24 hours or on the same day if they have higher-risk clinical symptoms.

Since the start of the Covid-19 pandemic, we are concerned that local referrals to our vascular neurology Rasp outpatient service have decreased by at least 50 to 80 per cent over a three-week period compared with a similar time period in 2019.

Anecdotally, a trend towards reduced referrals and attendances with suspected TIAs is also happening in other parts of the country and is also occurring internationally. The same has happened with stroke.

Some patients might be having difficulty getting through to their own GPs due to their GPs extremely busy workloads, but we suspect some patients may simply be afraid to present to their GPs or emergency department with symptoms of suspected TIAs, or are dismissing such symptoms because of fear of contracting Covid-19 if they attend hospital.

Busy doctors are never looking for more work, but if patients have had symptoms suggestive of a TIA, we advise that they must make urgent contact with their GP, or attend their local emergency department if they cannot access their GP, or if symptoms occur outside of normal working hours, for immediate assessment. GPs or emergency department staff can then refer patients for urgent vascular neurology and stroke specialist assessment at their local service Rasp service if a TIA is suspected.

Practices vary through the country, but in our own hospital we have maintained access to expedited outpatient specialised blood tests and neurovascular investigations, with face-to-face assessments in appropriate personal protective equipment by a consultant with expertise in TIA and stroke care to establish an accurate diagnosis and begin urgent treatment to optimally prevent a potentially disabling stroke on the same day.

We also advise selected patients if a brief inpatient stay for other urgent investigations or treatment is necessary.

With this expedited approach, international studies indicate that one can prevent more than 80 per cent of strokes following a TIA if we are given the opportunity to do so.

Therefore, the message is to stay safe and follow all HSE guidelines on Covid-19 regarding social distancing, self-isolation and cocooning, etc, but please do not ignore your symptoms and do not stay at home if you have had a suspected TIA which needs urgent medical assessment and treatment. Yours, etc,

Prof DOMINICK

McCABE,

Dr ALLAN

McCARTHY,

Consultant Neurologists,

Tallaght University

Hospital.

Read more here:
Stroke prevention during the pandemic - The Irish Times

Erenumab Improves Daily Functioning and Quality of Life – Neurology Times

Interim analysis of erenumab (Aimovig; Novartis) from the TELESCOPE study confirmed the monoclonal antibodys real-world and long-term safety and benefit in patients with episodic and chronic migraine.1,2

Data included 109 patients from Germany, and showed an average reduction of 8 migraine days with erenumab therapy. Additionally, 80% of the patients felt a reduction of intensity and 92% of patients had a reduction of frequency of their attacks. Using global impression scores, treating physicians noted 80% of the patients were rated as much improved or very much improved after receiving erenumab.

These data from TELESCOPE were accepted to the American Academy of Neurology (AAN) 2020 Annual Meeting. Erenumab, the first-in-class fully human monoclonal antibody against calcitonin-gene-related-peptide (CGRP) was approved by the FDA in May 2018 for the prevention of migraine after it showed significant improvement in 3 different clinical trials.

In addition to the aforementioned reduction of migraine days, treatment with erenumab triggered a first response in 75% of patients after their first injection.

These newly shared data reinforce Novartiss commitment to reimagine migraine care and add to the growing body of real world and long-term evidence demonstrating the efficacy of Aimovig for migraine prevention across the migraine spectrum, Estelle Vester-Blokland, MD, global head, Neuroscience Medical Affairs, Novartis Pharmaceuticals, said in a statement.

The TELESCOPE study included data from 70 headache centers from July 2019 to December 2019, and initially aimed to characterize the use of erenumab with regard to therapy decision, patient profiles, and quality of life from the treating patients perspective. Following that evaluation, each center documented the treatment effects and satisfaction of treatment outcomes in 1020 individual and consecutive patients with episodic and chronic migraine already into 3 months of erenumab treatment.

Novartis also announced interim results from the real-world PERISCOPE study, which included 91 patients who received erenumab with an overall mean disease duration of 18 years. Data showed that 85% of patients who received erenumab could cope better with daily activities and 83% lost fewer days to migraine since the start of their treatment.2

Long-term data results from a 4.5-year interim analysis of the open-label treatment phase of the phase 2 clinical trial demonstrated sustained reductions in monthly migraine days in patients with episodic migraine who received erenumab. An average of 5.8 fewer monthly migraine days were observed in patients who switched from 70 mg to 140 mg and remained on 140-mg erenumab for >4 years.

Novartis and Amgen are proud to lead the way based on the vast breadth of experience with Aimovig in showing how patients can take their life back from this highly debilitating disease, Vester-Blokland continued.

References:

REFERENCES1. Straube A, Stude P, Gaul C, Koch M, Schuh K. First one-year real world evidence data with the monoclonal antibody erenumab in Germany. Neurology. 2020;94 (15 Suppl). 18732. Novartis announces data in Neurology reinforcing the real-world and long-term effectiveness and safety of Aimovig as a preventive treatment across the full spectrium of migraine [news release]. Basel, Switzerland: Novartis; Published April 16, 2020. Accessed April 22, 2020. novartis.com/news/media-releases/novartis-announces-data-neurology-reinforcing-real-world-and-long-term-effectiveness-and-safety-aimovig-preventive-treatment-across-full-spectrum-migraine.

Go here to see the original:
Erenumab Improves Daily Functioning and Quality of Life - Neurology Times

Trials and Tribulations: Neurology Research During COVID-19 – Medscape

With some pivotal trials on hold, the COVID-19 pandemic is slowing the pace of research in Alzheimer's disease (AD), stroke, and multiple sclerosis (MS).

However, researchers remain determined to forge ahead with many redesigning their studies, at least in part to optimize the safety of their participants and research staff.

Keeping people engaged while protocols are on hold; expanding normal safety considerations; and re-enlisting statisticians to keep their findings as significant as possible are just some of study survival strategies underway.

The pandemic is having a significant impact on Alzheimer's research, and medical research in general, says Heather Snyder, PhD, vice president, Medical & Scientific Relations at theAlzheimer's Association.

"Many clinical trials worldwide are pausing, changing, or halting the testing of the drug or the intervention," she told Medscape Medical News. "How the teams have adapted depends on the study," she added. "As you can imagine, things are changing on a daily basis."

The US Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) trial, for example, is on hold until at least May 31. The Alzheimer's Association is helping to implement and fund the study along with Wake Forest University Medical Center.

"We're not randomizing participants at this point in time and the intervention which is based on a team meeting, and there is a social aspect to that has been paused," Snyder said.

Another pivotal study underway is the Anti-Amyloid Treatment in Asymptomatic Alzheimers study (the A4 Study). Investigators are evaluating if an anti-amyloid antibody, solanezumab (Eli Lilly and Co), can slow memory loss among people with amyloid on imaging but no symptoms of cognitive decline at baseline.

"The A4 Study is definitely continuing. However, in an effort tominimize risk to participants, site staff and study integrity, we have implemented an optional study hiatus for both the double-blind andopen-label extension phases," lead investigator Reisa Anne Sperling, MD, told Medscape Medical News.

"We wanted to prioritize the safety of our participants as well as theability of participants to remain in the studydespitedisruptions from the COVID-19 pandemic," said Sperling, who is professor of neurology at Harvard Medical School and director of the Center forAlzheimer Research andTreatment at Brigham and Women'sHospital andMassachusetts GeneralHospital in Boston.

The ultimate goal is for A4 participants to receive the full number of planned infusions and assessments, even if it takes longer, she added.

Many AD researchers outside the United States face similar challenges. "As you probably are well aware, Spain is now in a complete lockdown. This has affected research centers like ours, Barcelonaeta Brain Research Center, and the way we work," Jos Lus Molinuevo Guix, MD, PhD, told Medscape Medical News.

All participants in observational studies like the ALFA+ study and EPAD initiatives, as well as those in trials including PENSA and AB1601, "are not allowed, by law, to come in, hence from a safety perspective we are on good grounds," added Molinuevo Guix, who directs the Alzheimer's disease and other cognitive disorders unit at the Hospital Clinic de Barcelona.

The investigators are creating protocols for communicating with participants during the pandemic and for restarting visits safely after the lockdown has ended.

A similar situation is occurring in stroke trials. Stroke is "obviously an acute disease, as well as a disease that requires secondary prevention," Mitchell Elkind, MD, president-elect of the American Heart Association, told Medscape Medical News.

"One could argue that patients with stroke are going to be in the hospital anyway why not enroll them in a study? They're not incurring any additional risk," he said. "But the staff have to come in to see them, and we're really trying to avoid exposure."

One ongoing trial, the AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke (ARCADIA), stopped randomly assigning new participants to secondary prevention with apixaban or aspirin because of COVID-19. However, Elkind and colleagues plan to provide medication to the 440 people already in the trial.

"Wherever possible, the study coordinators are shipping the drug to people and doing follow-up visits by phone or video," said Elkind, chief of the Division of Neurology Clinical Outcomes Research and Population Sciences at Columbia University in New York City.

Protecting patients, staff, and ultimately society is a "major driving force in stopping the randomizations," he stressed.

ARCADIA is part of the StrokeNet prevention trials network, run by the NIH's National Institute of Neurologic Disorders and Stroke (NINDS). Additional pivotal trials include the Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST) and the Multi-arm Optimization of Stroke Thrombolysis (MOST) studies, he said.

Joseph Broderick, MD, director of the national NIH StrokeNet, agreed that safety comes first. "It was the decision of the StrokeNet leadership and the principal investigators of the trials that we needed to hold recruitment of new patients while we worked on adapting processes of enrollment to ensure the safety of both patients and researchers interacting with study patients," he told Medscape Medical News.

Potential risks vary based on the study intervention and the need for in-person interactions. Trials that include stimulation devices or physical therapy, for example, might be most affected, added Broderick, professor and director of the UC Gardner Neuroscience Institute at the University of Cincinnati in Ohio.

Nevertheless, "there are potential waysto move as much as possible toward telemedicine and digital interactions during this time."

At the national level, the COVID-19 pandemic has had an "unprecedented impact on almost all the clinical trials funded by NINDS," said Clinton Wright, MD, director of the Division of Clinical Research at NINDS. "Investigators have had to adapt quickly."

Supplementing existing grants with money to conduct research on COVID-19 and pursuing research opportunities from different institutes are "some of the creative approaches [that] have come from the NIH [National Institutes of Health] itself," Wright said. "Other creative approaches have come from investigators trying to keep their studies and trials going during the pandemic."

In clinical trials, "everything from electronic consent to in-home research drug delivery is being brought to bear."

"A few ongoing trials have been able to modify their protocols to obtain consent and carry out evaluations remotely by telephone or videoconferencing," Wright said. "This is especially critical for trials that involve medical management of specific risk factors or conditions, where suspension of the trial could itself have adverse consequences due to reduced engagement with research participants."

For participants already in MS studies, "each upcoming visit is assessed for whether it's critical or could be done virtually or just skipped. If a person needs a treatment that cannot be postponed or skipped, they come in," Jeffrey Cohen, MD, director of the Experimental Therapeutics Program at theMellen Center for Multiple Sclerosis Treatment and Researchat the Cleveland Clinic, Ohio, told Medscape Medical News.

New study enrollment is largely on hold and study visits for existing participants are limited, said Cohen, who is also president of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS).

Some of the major ongoing trials in MS are "looking at very fundamental questions in the field," Cohen said. The Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS (DELIVER-MS) and Traditional Versus Early Aggressive Therapy for Multiple Sclerosis (TREAT-MS) trials, for example, evaluate whether treatment should be initiated with one of the less efficacious agents with escalation as needed, or whether treatment should begin with a high-efficacy agent.

Both trials are currently on hold because of the pandemic, as is the Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) study.

"There has been a lot of interest in hematopoietic stem cell transplants and where they fit into our overall treatment strategy, and this is intended to provide a more definitive answer," Cohen said.

"The pandemic has been challenging" in terms of ongoing MS research, said Benjamin M. Segal, MD, chair of the Department of Neurology and director of the Neuroscience Research Institute at The Ohio State University Wexner Medical Center, Columbus.

"With regard to the lab, our animal model experiments have been placed on hold.We have stopped collecting samples from clinical subjects for biomarker studies.

"However, my research team has been taking advantage of the time that has been freed up from bench work by analyzing data sets that had been placed aside, delving more deeply into the literature, and writing new grant proposals and articles," he added.

Two of Segal's traineesare writing review articles on the immunopathogenesis of MS and its treatment. Another postdoctoral candidate is writing a grant proposal to investigate how coinfection with a coronavirus modulates CNS pathology and the clinical course of an animal model of MS.

"I am asking my trainees to plan out experiments further in advance than they ever have before, so they are as prepared as possible to resume their research agendas once we are up and running again," Segal said.

Confronting current challenges while planning for a future less disrupted by the pandemic is a common theme that emerges.

"The duration of this [pandemic] will dictate how we analyze the data at the end [for the US POINTER study]. There is a large group of statisticians working on this," Snyder said.

Harvard Medical School's Sperling also remains undeterred.

"This is definitely a challenging time, as we must not allow the COVID-19 to interfere with our essential mission to find a successful treatment to prevent cognitive decline in AD. We do need, however, to be asflexible as possible to protect our participants and minimize the impact to our overall study integrity," she said.

Molinuevo Guix, of the Barcelonaeta Brain Research Center, is also determined to continue his AD research.

"I am aware that after the crisis, there will be less [risk] but still a COVID-19 infection risk, so apart from trying to generate part of our visits virtually, we want to make sure we have all necessary safety measures in place. We remain very active to preserve the work we have done to keep up the fight against Alzheimer's and dementia," he said

Such forward thinking also applies to major stroke trials, said University of Cincinnati's Broderick.

"As soon as we shut down enrollment in stroke trials, we immediately began to make plans about how and when we can restart our stroke trials," he explained. "One of our trials can do every step of the trial process remotely without direct in-person interactions and will be able to restart soon."

An individualized approach is needed, Broderick added.

"For trials involving necessary in-person and hands-on assessments, we will need to consider how best to use protective equipment and expanded testing that will likely match the ongoing clinical care and requirements at a given institution.

"Even if a trial officially reopens enrollment, the decision to enroll locally will need to follow local institutional environment and guidelines. Thus, restart of trial enrollment will not likely be uniform, similar to how trials often start in the first place," Broderick added.

The NIH published uniform standards for researchers across its institutes to help guide them during the pandemic.

Future contingency plans also are underway at the NINDS.

"As the pandemic wanes and in-person research activities restart, it will be important to have in place safety measures that prevent a resurgence of the virus, such as proper personal protective equipment for staff and research participants, said Wright, the clinical research director at NINDS.

For clinical trials, NINDS is prepared to provide supplemental funds to trial investigators to help support additional activities undertaken as a result of the pandemic.

"This has been an instructive experience.The pandemic will end, and we will resume much of our old patterns of behavior," said Ohio State's Segal."But some of the strategies that we have employed to get through this time will continue to influence the way we communicate information, plan experiments, and prioritize research activities in the future, to good effect."

Snyder, Sperling, Molinuevo Guix, Elkind, Broderick, Wright, Cohen, and Segal have disclosed no relevant disclosures.

Follow Damian McNamara on Twitter: @MedReporter. For more Medscape Neurology news, join us on Facebook and Twitter.

Read more:
Trials and Tribulations: Neurology Research During COVID-19 - Medscape

In the Age of Digital Medicine, This Humble Medical Tool Hangs On – Medscape

Receiving a diagnosis in 2020 at least one made at a medical center outfitted with the latest clinical gadgetry might include a scan that divides your body into a bread loaf of high-resolution digital slices. Your DNA might be fed through a gene sequencer that spits out your mortal code in a matter of hours. Even your smartphone is being used to uncover health problems and could maybe even help in detecting COVID-19 symptoms.

Yet nearly 130 years since its inception, after decades of science has mapped out our neuronal pathways, a simple knob of rubber with a metal handle remains one of medicine's most essential tools. I'm referring to the cheap, portable, easy-to-use reflex hammer.

This unassuming device can be invaluable in diagnosing nervous and muscular disorders, and in determining whether a patient's pathology lies in the brain or elsewhere in the body. It can also help curtail healthcare spending by preventing unnecessary, often expensive testing. Yet like so many major medical and scientific discoveries, the reflex hammer has humble origins in this case, the basement of a Viennese hotel.

The inn was run by the father of Leopold Auenbrugger, an 18th century doctor who is considered to be among the founders of modern medicine. To gauge how much wine was left for customers, hotel employees would thump casks with their hands and listen for a dull thud or hollow tympany. Auenbrugger realized that the same technique, now called "percussing," could be applied to the human torso to, say, determine how much fluid had built up around a diseased heart. He wrote as much in his 1761 paper "New invention to detect diseases hidden deep within the chest."

Leopold Auenbrugger (here with his wife, Marianne) is regarded as one of the founders of modern medicine, having applied the idea of detecting disease by sound.

Thought to be more accurate than the human hand, it wasn't long before percussion hammers were being designed to more precisely diagnose disease. Competition ensued.

Scottish physician Sir David Barry's model, released in the 1820s, was the first. German doctor Max A. Wintrich's came shortly after and was more popular but was not without its critics: "[Wintrich's hammer] is inconvenient to hold, it is rigid ... it required education to use it, and even then it does not fulfill its purposes," a rival inventor commented.

As neurologist Douglas J. Lanska wrote in a 1989 paper on the many types of reflex hammers, "Some were T-shaped or L-shaped, others resembled battle axes, tomahawks, or even magic wands." He adds that no material was off-limits: wood, ebony, whale bone, brass, lead, even "velvet-covered worsted" (a type of yarn).

As percussion hammer warfare waged on, doctors and scientists were also beginning to understand the concept of reflexes, or involuntary, near-immediate responses to stimuli that occur before any sensory information reaches the brain. Muscular jerks. Blinking. Sneezing. Gagging. All of these are automatic feedback loops between sensory and motor neurons that help us navigate our environment and protect us from danger.

In 1875, German neurologists Heinrich Erb and Carl Friedrich Otto Westphal were among the first to realize that eliciting a reflex by briskly tapping the tendons of major muscles might be useful. They felt that the knee jerk or "patellar-tendon" reflex in particular could help assess nerve function.

Anton Wintrich introduced this percussion hammer model in 1841.

Hammers specifically suited to test reflexes were soon developed, the first of which had the now classic shape we're accustomed to, a thin metal handle with a triangular rubber head. Designed by American physician John Madison Taylor in Philadelphia in 1888 and modified ever since by many the simple device was heavy enough to elicit reflexes and had round edges to ease impact. An entry-level model runs just $6.99 on Amazon.

The Krauss hammer, developed by German-American physician William Christopher Krauss, was designed around the same time. It had two rounded heads: a large one for knees and a smaller one for biceps. Dr Ernst L.O. Trmner's did too, but it tapered to a thin end to assess skin reflexes. There were also the Queen Square hammer, the Babinski hammer, the Buck hammer, and the Berliner hammer. The Stookey hammer flaunted a camel hair brush to get a better sense of touch sensation. The list goes on.

Daniella C. Sisniega is a neurology resident at Mt. Sinai Medical Center. At the 2017 American Academy of Neurology annual meeting, while still a medical student, she presented a poster explicating the reflex hammer's past. "I'm fascinated by how the reflex hammer started out as a percussion hammer but was [then] adapted to elicit reflexes and has been in every neurologist's tool box ever since," she says.

"I also did not know that the little rubber triangle was the first reflex hammer. I feel like I owe it an apology!" she joked, referring to the often lackluster quality of the inexpensive Taylors.

"The little tomahawk is included in the kit everyone receives when they enter medical school," she recalls. "The rubber is cheap and very light, while the other hammers are heavier on the head so that you can use the 'swing' of the hammer as opposed to the strength of the strike to test the reflex."

While welcoming technological advances in medicine, Mt. Sinai School of Medicine neurologist and multiple sclerosis expert Stephen Krieger doesnt hedge on the role of the reflex hammer in modern medical diagnosis.

"We could argue about the nuances of the hammer the Queen Square, the Tomahawk, plastic handle, metal handle, weighted, flexible or rigid but the hammer itself is always in the hand. Reflexes tell the story of neurologic diseases of all sorts," he says.

Krieger explains how disorders of the brain, like a stroke or brain tumor, result in hyperactive reflexes, while conditions affecting muscles and peripheral nerves usually result in reduced or nonexistent reflexes. Reduced reflexes, for example, are a common symptom of back pain due to degenerative disk disease.

Dr Andrew Wilner, a long-time Medscape contributor and staff neurologist at a county hospital in Memphis, Tennessee, recounts the story of one of his patients, who had back pain, weakness, and numbness of the legs. Wilner was leaning toward a diagnosis of either Guillain-Barr syndrome (GBS) an autoimmune disorder of peripheral nerves or a myelopathy, an injury of some kind to the spinal cord. Both conditions can lead to medical emergencies, but each requires drastically different treatment.

"The reflex hammer was arguably our most important tool in narrowing down the differential diagnosis," he says. "Had we found diminished or absent deep tendon reflexes, GBS would have been more likely. As it turned out, the patient had brisk pathological knee jerks, pointing to a lesion in the brain or spinal cord."

On the basis of these findings, Wilner ordered an imaging study of the patient's spinal cord, where a lesion was found as opposed to pursuing the costly tests involved in a GBS diagnosis.

Wilner feels that the simple art of interviewing and examining a patient can get overshadowed by the myriad new diagnostic technologies. When it comes to clinical tools, he feels that sometimes basic is better.

"Technology is glorious," admits Krieger, "and [it] will teach us things about patients that we could never have known or imagined. But the simple, elegant, inexpensive, almost plebeian swing of the reflex hammer has a cost-benefit ratio that I think no advanced technology will likely ever match."

This article originally appeared on Shots, NPR's health blog.

Follow Medscape on Facebook, Twitter, Instagram, and YouTube

See more here:
In the Age of Digital Medicine, This Humble Medical Tool Hangs On - Medscape

Dr. Vinay Chaudhry Receives Distinguished Researcher Award – Newswise

Newswise The American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) is honoring Vinay Chaudhry, MD, with the 2020 AANEM Distinguished Researcher Award for his many years of dedicated research and outstanding clinical care of patients with neuromuscular (NM) diseases.

Dr. Chaudhry has made significant contributions to research throughout his career. He has received more than 40 research grants, and is currently participating in 15 ongoing NM clinical trials. He has also been an author on over 80 peer-reviewed publications, over 20 book chapters, as well as more than 75 published abstracts. He has been in the forefront of defining clinical, electrophysiological, and IVIG responsiveness of multifocal motor neuropathy (MMN), a disease close to his heart.He has published extensively on chemotherapy-induced polyneuropathies (CIPN) from taxol, vincristine, suramin, thalidomide, and bortezomib. These papers have emphasized the dose-dependent nature of neuropathy and patterns of length-dependent distal symmetric neuropathy versus the nonlength dependent neuropathy.

"I continue to be involved in trials of myasthenia gravis, amyotrophic lateral sclerosis (ALS), and amyloid neuropathy. Electrophysiology remains the cornerstone of all my research and I have worked on several projects including motor unit estimates, motor unit number index, neuronal excitability studies, and electrophysiological methodological studies in ALS," Dr. Chaudhry said.

Dr. Chaudhry has been active in the AANEM for many years. He served as chair for both the AANEM CME Advisory Committee and the Journal Committee. He was a member of the Neuromuscular Vision Task Force, Membership & Ethics committee, and has served on the Muscle & Nerve Editorial Board. Dr. Chaudhry was also actively involved with ABEM, serving as an examiner for the ABEM certification exams in 2002, 2003, and 2007- 2013 and as the ABEM Secretary. AANEM is important to Dr. Chaudhry.

AANEM is a special organization of the physicians, by the physicians, and for the physicians practicing neuromuscular and electrodiagnostic medicine, said Dr. Chaudhry. AANEM meetings make me feel completely at home, providing the perfect opportunity to lean on, teach and interact with colleagues practicing in your field."

Dr. Chaudhry is currently a Professor of Neurology at John Hopkins University School of Medicine and Director of Neurology EMG Laboratory at the John Hopkins Hospital. At Johns Hopkins, he has also served as the Vice Chair of Clinical Affairs and Director of the Neurology Outpatient Center (2002-2013), and Director of Clinical Neurophysiology/Neuromuscular Fellowships (1996-2005), and Director of Neuromuscular Division (2001-2004). Dr. Chaudhry has been a member of AANEM since 1989 and has presented at over 20 sessions and symposiums at AANEM Annual Meetings since 1997. Dr. Chaudhry received his medical degree from the All-India Institute of Medical Services in New Delhi, India. He became house officer in internal medicine at Preston Hospital & Tynemouth Victoria Jubilee Infirmary in North Shields, England and senior house officer in internal medicine at Llanelli Hospital in Wales, United Kingdom. He obtained membership in the Royal College of Physicians (M.R.C.P.), equivalent to board certification in internal medicine. He went on to complete a residency in neurology at the University of Tennessee Center for Health Sciences and the University of Alabama in Birmingham. He was the chief resident during his last year of training. He then trained at Johns Hopkins, receiving subspecialty training in clinical and research aspects of neuromuscular diseases. Dr. Chaudhry has also been active with the American Academy of Neurology (AAN) serving on the board of directors from 2007 to 2011 and the chair of NM section of AAN (2001-2005). It was under his leadership that the Accreditation Council for Graduate Medical Education (ACGME) subspecialty NM examination was created.

About the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM)

Based in Rochester, Minnesota, the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) is the premier nonprofit membership association dedicated to the advancement of neuromuscular (NM), musculoskeletal and electrodiagnostic (EDX) medicine. The organization and its members work to improve the quality of patient care and advance the science of NM diseases and EDX medicine by serving physicians and allied health professionals who care for those with muscle and nerve disorders.

Visit link:
Dr. Vinay Chaudhry Receives Distinguished Researcher Award - Newswise

More Than Words: Neurologic Societies Take Action On… : Neurology Today – LWW Journals

Article In Brief

The AAN, the American Neurological Association, and the American Epilepsy Society have responded to the call for action to address systemic racismwith initiatives that look specifically at what the field of neurology can do.

The American Academy of Neurology and other neurology organizations, like many other medical organizations, are grappling with the problem of systemic racism in health care and in their own organizations. And they have committed to taking sustained and specific actions to become genuinely anti-racist organizations.

Strong public statements are important, but we have to put action behind them, AAN President James C. Stevens, MD, FAAN, a specialist in sleep disorders medicine at the Fort Wayne Neurological Center in Indiana, told Neurology Today in a telephone interview.

Beginning in 2014, the AAN created its Diversity Leadership Program, and since then a variety of other task forces and leadership groups have worked on addressing issues of inequity, diversity, and inclusion within neurology and in the Academy.

In the fall of 2018, the Joint Coordinating Council on Equity, Diversity, Inclusion, and Disparities was established to ensure that recommendations from these groups, including the Diversity Leadership Program, Gender Disparities Task Force, and the Health Care Disparities Task Force, would be implemented across the entire organization.

But although a lot of work has been done, events of the past few months, including the heinous murder of George Floyd in Minneapolis, the home of AAN headquarters, have rightly focused people's attention on these injustices, and demonstrated that we must do much more, Dr. Stevens said.

So in early June, the Academy announced the creation of a special commission to recommend specific short-term and long-term action steps for the AAN to take toward becoming an anti-racist organization.

The AAN commits to enact sustained change for our members and patients, Dr. Stevens said in a statement released at the time. In this historic moment, we are resolved to pursue bold action beyond rhetoric and stand with the communities we serve to eliminate inequities that are antithetical to our values and the pursuit of our vision and mission.

These action steps will be presented to the AAN Board of Directors for review and approval by late summer.

What we need is not a knee-jerk, one-time response, but a sustained change in the way the organization approaches these issues, said Jeffrey McClean II, MD, FAAN, chair of the AAN Equity, Diversity, and Inclusion Joint Coordinating Council. That's why we created this special commission, to take a deep dive into the organization and the field and look comprehensively at what changes need to be made, both now and in the future, to sustainably move toward that ideal of being a fully inclusive and anti-racist organization.

The AAN Board charged the special commission to address two broad areas of focus: (1) the AAN itselfboth its structural composition and its programmatic workand changes necessary to achieve anti-racist goals; and (2) disparities in care, particularly within neurology and the neurosciences, and how the Academy can use its influence, resources, and expertise to mitigate and reduce these disparities.

The special commission includes chairs or vice chairs of all the major AAN committees, as well as chairs or editors-in-chief of all other major entities in the Academy, including its publications.

We have expertise about how the organization works and what it does from top to bottom, said Dr. McClean. We have combined that expertise and influence with a number of at-large members who have spent a lot of time working on issues related to equity, diversity, inclusion, anti-racism, and social justice.

Since early June, the special commission has conducted several large group meetings and small group breakouts (all virtual), and researched organizations in multiple different fields that have pursued organizational change to become anti-racistmost of them outside medicine.

We've used those lessons to inform us as we evaluate where the Academy is now, and what concrete steps to take toward becoming an anti-racist organization, Dr. McClean said.

Groundwork for the commission's work was also laid by a powerful presentation from members of the AAN's Emerging Leaders Program, who had been charged in October of 2019 with researching the question of how the Academy could become a fully inclusive society.

They were detailed in their recommendations and gave us a vision for the Academy moving forward, which really formed the foundation for the special commission as we looked into specific things to recommend to the Board of Directors, Dr. McClean said.

The special commission recently finalized its report for review, first by the Equity, Diversity and Inclusion Joint Coordinating Council and then by the AAN Board of Directors. The report and recommendations will be released publicly in the fall.

Even as the special commission conducted its work, further actions to pursue anti-racist goals were already underway at the AAN. In July, the AAN and Neurology Today hosted a webcast on health care disparities in the time of COVID-19, featuring Richard S. Isaacson, MD, FAAN, founder and director of the Alzheimer's Prevention Clinic at NewYork-Presbyterian/Weill Cornell Medical Center and Richard T. Benson, MD, PhD, director of the Office of Global Health and Health Disparities in the Division of Clinical Research at the National Institute of Neurologic Disorders and Stroke.

The broadcast focused on what AAN members can do to reduce disparities within their institution, how NIH and NINDS are working to address health care disparities across the country, and the importance of developing a diverse pipeline.

And on July 22, the AAN announced the establishment of a new Underrepresented in Neurology section, formed by leaders from the Society of Black Neurologists (SBN).

SBN was created about 18 months ago, explained Jimmy V. Berthaud, MD, MPH, an assistant professor in the department of neurology at the University of Michigan Medical School. At the time, there was really no overarching group for underrepresented minorities in the field of neurology to come together, so a small group of us decided to form a society on Facebook.

After SBN had reached more than 100 membersit now has more than 200Dr. Berthaud and other group leaders approached Dr. McClean about creating an official AAN Section. Less than a month after its founding in July 2020, the new section already had more than 50 members.

And in June, the SBN authored a powerful message on Neurology's blog site. Many of us have had the unfortunate experience of being called Ngger and other derogatory words by patients and colleagues. We are often mistaken for other health care workerscommonly janitors, maids, food service workers, and nurseseven while wearing our white coats and identification badges, wrote Dr. Berthaud and colleagues, including Ima Ebong, MD; Aaron Anderson, MD; Shaun Smart, MD; Uzo Ugochukwu, MD; and Andrew Spector, MD.

If not wearing our white coats, we are often not recognized by our colleagues in the hallways of our hospitals and clinics. We endure daily microaggressions regarding our physical appearances, including chosen styles of hair, and choice of attire. Yet we still pride ourselves to provide the best unbiased care possible to patients of all races, regardless of their perceptions of us as Black people.

The SBN and the section's immediate goals are to significantly increase their numbers and help to grow the pipeline of people of color coming into the field. Only about 2 to 3 percent of practicing neurologists are Black, and we want to increase those numbers, Dr. Berthaud told Neurology Today. For example, we recently held a Zoom forum for current medical students on how to apply for neurology residency positions, which had about 25 to 30 participants.

Like the AAN, the American Neurological Association (ANA), which represents academic neurologists and neuroscientists, is undergoing a similar self-examination on issues of race.

We first had to accept the fact that for the 143 years of our existence, we have been a relatively exclusionary society, says ANA President Justin C. McArthur, MBBS, FAAN, FANA, chair and professor of neurology at Johns Hopkins and founding director the of the Johns Hopkins/National Institute of Mental Health Research Center for Novel Therapeutics of HIV-associated Cognitive Disorders.

Until 15 years ago you could only get into the ANA by being nominated and selected. Those rules were changed with the intent of making the ANA more diverse, younger and more forward-looking, but in terms of social justice and equity, we know that the ANA has to take concrete steps to move us from where we were as an organization toward where we want to be.

The organization has created a new task force on Inclusion, Diversity, Equity, Anti-Racism and Social Justice (IDEAS) to address the diversity of its membership and representational leadership and fund health care disparities research. IDEAS has established an endowed lectureship in the name of Audrey Penn, MD, the first and only Black woman president of the ANA, who will help the organization select its first speaker for 2021.

The ANA has also developed a social justice Zoom series in partnership with Johns Hopkins, with sessions every Thursday from July into early September. We will have a series of speakers educating our members about systemic racism, implicit bias, and structural elements in our society that have led to health care disparities, said Dr. McArthur. Nearly 200 participants joined the first session, which featured Maya R. Cummings, PhD, former chair of the Maryland Democratic Party and the widow of Congressman Elijah Cummings (D-MD).

In October, the ANA will host a four-hour social justice symposium as part of its virtual Annual Meeting, which will include the presentation of a member survey on diversity and equity and a keynote address from Valencia Walker, MD, assistant dean for equity and diversity inclusion at the David Geffen School of Medicine at UCLA.

We are committed to making this a durable response, one that is self-sustaining, said Dr. McArthur. We have to be accountable for our outcomes and will use the social justice symposium at the ANA annual meeting to help us set those metrics. It's not a six-week feel-good campaign. We have been heavily influenced by some of our members of color who have courageously spoken up to candidly tell us that some of them do not feel welcome in our organization. That's a tough thing to say and we owe it to them to take change very seriously.

At the subspecialty society level, one organization that is planning significant, specific changes is the American Epilepsy Society (AES).

We have had an ongoing effort focused on diversity for the last several years, including a special task force on diversity in gender, and we had been working toward efforts on racial equity when the killings of George Floyd, Ahmaud Arbery and Breonna Taylor brought this issue to the forefront, said AES President William D. Gaillard, MD, FAAN, chief of the divisions of child neurology, epilepsy and neurophysiology at Children's National Hospital.

In response, we have created a Diversity, Equity and Inclusion Task Force, which will report to our board in September on goals and actions to embed in our new strategic plan.

Dr. Gaillard promises that the AES will embed within that strategic plan an ongoing process of addressing all levels of diversity, inclusion and equity, including the creation of a senior-level committee with ongoing responsibilities related to equity, diversity and anti-racism. The AES is also expanding on three existing efforts: These include prioritization of diversity, equity, and inclusion in the AES Fellows Program; an annual poster session at the AES Annual Meeting Better Patient Outcomes through Diversity; and governance that focuses on addressing diversity in appointments to serve on AES committees.

We view this as a long-term process, understanding that it requires constant effort, he said. This is one of those moments where I think it's possible to implement change because there is interest, enthusiasm, and a will to do things better.

While awaiting the release of the AAN special commission's recommendations in the fall, all neurologists can take action, starting with recommendations from the SBN's blog post.

Start with listening and most importantly believing when you hear what life is like for Black Americans, the SBN authors of the blog post wrote. The stories are not exaggerated. Take time to educate yourself with books like How to Be an Antiracist by Prof. Ibram X. Kendi, Black Man in a White Coat by Dr. Damon Tweedy, Medical Apartheid: The Dark History of Medical Experimentation on Black Americans from Colonial Times to the Present by Harriet Washington, or any of a number of similar resources. It is every physician's responsibility to learn what we can about a problem that is killing so many people.

Given the history of race and racism in our country, our society and in health care, the continuation of the effects of race and racism does not require that people actively perpetuate that system, said Dr. McClean. It has become self-perpetuating and it won't resolve on its own with time or even with increased diversity. It requires purposeful, proactive, and sustained action in order to reverse these things that have plagued our society for hundreds of years.

Read more:
More Than Words: Neurologic Societies Take Action On... : Neurology Today - LWW Journals

Gilead, Maker Of Remdesivir, Criticized As ‘Taking Advantage Of The Situation’ – Kaiser Health News

Other pharmaceutical news is on orphan drugs, ALS trials, Theranos and more.

ABC News:For Company Behind Coronavirus Drug, Sharp Questions Over Pricing, Potentially Cheaper OptionAfter initial excitement about the discovery of a promising treatment for some coronavirus patients, executives with Gilead Sciences are now facing harsh criticism over the initial business decisions theyve made in the midst of a pandemic. In recent days, state leaders and a government watchdog group have leveled complaints against the company for the price point it set for its antiviral drug remdesivir, a promising treatment shown to diminish recovery time in hospitalized coronavirus patients, and for allegedly not more quickly pursing a potentially cheaper alternative. Gilead holds exclusive manufacturing rights for remdesivir. (Bruggeman, 8/13)

Stat:A Long-Awaited Report On Orphan Drugs In Europe Suggests Incentives To Pharma Need ChangeAfter being kept under wraps for a year, an expansive review of European regulations designed to spur development of drugs for rare diseases and children found the number of medicines has increased. But at the same time, drug makers often did not address some of the most urgent needs. Instead, the pharmaceutical industry sometimes targeted more profitable therapeutic areas, raising questions about whether incentives offered to the pharmaceutical industry should be changed, according to the long-awaited report from the European Commission. As in the U.S., these incentives include market exclusivity for a period of time. (Silverman, 8/12)

Boston Globe:'Were Going To Keep Going': A New Clinical Trials For ALS Gives Patients HopeAs a cardiologist, Dr. Marc Litt has plenty of arrows in his quiver for patients with heart disease: Medications that thin blood. Drug-coated stents that widen blocked arteries. Implants that replace damaged valves in minimally invasive surgery. But when the 63-year-old physician was diagnosed with ALS in March 2019 at Massachusetts General Hospital, he was dismayed to see how little medicine had to offer him. (Saltzman, 8/12)

In other pharmaceutical industry news

San Jose Mercury News:Theranos Founder Elizabeth Holmes Twice-Delayed Trial To Start In March: JudgeAfter being delayed twice by the coronavirus pandemic, the criminal trial of Theranos founder Elizabeth Holmes has been scheduled to start in March. Holmes, a Stanford University dropout who founded her now-defunct Palo Alto blood-testing startup in 2003, is charged with a dozen felony counts of fraud, and has denied federal government allegations that she and her co-accused, former company president Sunny Balwani, misled doctors and patients and bilked investors out of hundreds of millions of dollars. (Baron, 8/11)

Stat:4 Questions For Neurology Startups As Investment SurgesAs pharmaceutical companies stepped back from developing new drugs for neurological conditions, venture capitalists took a big step forward. Venture investors have poured more than $500 million into early-stage neurology startups this year, according to a recent health care venture capital report from Silicon Valley Bank more than six times as much money that was invested in the same over the first six months of last year. (Sheridan, 8/12)

CNN:CEO Does 180 Zoom Calls In Three Days To Help Take Company PublicBeing in charge of a health care company during a pandemic is a ton of work just ask Eric Hobbs, CEO of Berkeley Lights, who met with 180 investors over Zoom over three and a half days and lost 10 pounds over the process. You don't have to go on a virtual roadshow to work tirelessly in the drug business nowadays. Major drug companies are racing to develop a Covid-19 vaccine. But Hobbs says it won't be easy to come up with one that works right off the bat. (La Monica, 8/12)

More here:
Gilead, Maker Of Remdesivir, Criticized As 'Taking Advantage Of The Situation' - Kaiser Health News

‘Covid fog’: The latest emerging, long-term symptom of Covid-19 – The Daily Briefing

Up to one-third of people who had Covid-19 report lingering neurological and psychological symptoms due to the disease, ranging from numb limbs to a mental slowness some people are calling "Covid fog"a finding that "reflect[s] a growing consensus that the disease can have lasting impact on the brain," Elizabeth Cooney reports for STAT News.

How Covid-19 will impact behavioral health services

According to Cooney, early reports from China and Europe revealed that some patients recovering from Covid-19, the disease caused by the new coronavirus, experienced anxiety and depression. Further, experts told STAT News that, in addition to mood disorders, they've seen patients who recovered from their coronavirus infections experience neuropsychological symptoms including dizziness, numbed limbs, brain fog, long-term loss of smell and taste, muscle weakness, and nerve damage so severe that patients struggled to walk. And that's on top of the long-term physical symptoms Covid-19 can cause, including damage to the heart, kidneys, and liver, Cooney reports.

Teodor Postolache, a professor of psychiatry at the University of Maryland School of Medicine, estimates that "between 30% and 50% of people with [a coronavirus] infection that has clinical manifestations are going to have some form of mental health issues," ranging from "anxiety or depression but also nonspecific symptoms that include fatigue, sleep, and waking abnormalities, a general sense of not being at your best, not being fully recovered in terms of the abilities of performing academically, occupationally, potentially physically."

John Bonfiglio, 64, reported many such symptoms after he recovered from a serious bout with Covid-19 at Newton-Wellesley Hospital, Cooney reports. Once Bonfiglio was finally transferred out of the ICUafter spending 17 days on a ventilatorhe said he was so confused that he forgot his name, forget where he was, and sometimes tried to slide from his bed to the floor.

Bonfiglio said he also felt more emotional than usual during his recovery and experienced persistent dizziness, hand tremors, and muscle weaknessso much so that he had to relearn how to walk. Bonfiglio said he's since regained some strength and the dizziness and tremors are now gone.

Similarly, Fred Pelzman, an internal medicine physician from New York who fell ill with Covid-19 in March, said he is still experiencing symptoms of the disease, including depressed abilities to taste and smell. And, according to Pelzman, his patients also have reported lingering effects from Covid-19, with one unable to complete simple math calculations in her head and others struggling to find correct words when communicating.

According to Cooney, researchers at the moment can say little "definitively about how best to prevent and treat neuropsychological manifestations of Covid-19. Nor do they know for certain why the brain is affected."

Victoria Pelak, a professor of neurology and ophthalmology at the University of Colorado School of Medicine, said treating Covid-19 patients with neurological symptoms has been like "trying to put out the fire." She explained, "Because you are so concerned with the raging fire," of Covid-19, "you haven't really been able to pay attention to the nervous system as much as you normally would."

But doctors have started putting some pieces together, Cooney writes. They think, for instance, that the new coronavirus damages the brain and nervous symptom through inflammation, not through a direct attack on those systems.

Lena Al-Harthi, chair of the department of microbial pathogens and immunity at Rush Medical College, explained that bits of the virusrather than the virus multiplyingcan spur the brain's inflammatory response.

"If you have an uncontrolled level of inflammation, that leads to toxicity and dysregulation," Al-Harthi said. "What I am concerned about is long-term effects, obviously in the [Covid-19 patients] who have been hospitalized, but I think it's definitely time to understand long-term sequelae for those individuals who have never been hospitalized"and it's not just limited to "older individuals," but includes "young [ones], too."

Physicians also are assessing whether the novel coronavirus is more likely than other viruses to cause a syndrome called demyelination, in which inflammation in the brain causes the immune system to attack the protective coating of nerve cells, Pelak said. According to Cooney, the syndrome can "cause weakness, numbness, and tingling. It can also disrupt how people think, in some cases spurring psychosis and hallucinations."

As for treating and preventing these longer-term issues, Ross ZafonteCMO at Spaulding Rehabilitation Hospital, which provides care to recovering Covid-19 patientssaid he's "trying to do a longitudinal study to see what are the comorbid factors." According to Zafonte, questions that need to be answered include: "What are the characteristics of people who don't get back to normal? How can early intervention try to deal with that? Are there some biomarkers of risk? [and] Can we try to define better targets for early intervention?"

Some physicians have voiced concerns about the long-term outlook for individuals who were infected with the coronavirus and are experiencing these symptoms. Postolache, for instance, said a coronavirus infection might serve as a "priming event," meaning that future stressors may reactivate the emotional and behavioral symptoms originally spurred by the infection. "We don't really say this is permanent," he said, "but considering all complexities of human life, it's unavoidable."

Wes Ely, a pulmonologist and critical care physician at Vanderbilt University Medical Center, echoed similar concerns, noting that while researchers will continue psychiatric evaluations and diagnostic imaging to get to the bottom of the symptoms, everything physicians know about the neurological symptoms of Covid-19 so far indicate that the disease could be "not only an acute problem," but "a chronic illness." Ely added, "The problem for these people is not over when they leave the hospital."

Keeping those factors in mind, Ely recommended three steps providers can take now to address the issue: "We can open the hospitals back up to the families" so patients are less isolated, "tell the families about [this issues] so that the families will know that this is coming," and offer "counseling and psychological help on the back end" (Cooney, STAT News, 8/12).

See the original post:
'Covid fog': The latest emerging, long-term symptom of Covid-19 - The Daily Briefing

Higgins announces $2.2 million grant to UB to support Parkinson’s research – UB Now: News and views for UB faculty and staff – University at Buffalo…

Rep. Brian Higgins has announced that UB has received a five-year, $2,224,925 grant from the National Institutes of Health to develop a method to diagnose Parkinsons disease (PD) before clinical symptoms are present.

The funding was awarded by the National Institute of Neurological Disorders and Stroke of the NIH. Principal investigator is Jian Feng, professor of physiology and biophysics in the Jacobs School of Medicine and Biomedical Sciences at UB.

Parkinsons is a motor system disorder resulting from the loss of dopamine-producing cells in the brain. It currently is diagnosed by neurologists observing and rating clinical symptoms based on a standard criteria. To even exhibit the onset of clinical symptoms of PD, one must experience many decades of cellular deterioration.

UBsresearch aims to transform Parkinsons research and therapeutic development with the ability to diagnose PD earlier, allowing for the possibility of proactively preventing or delaying severe neuron decay. The research, titled Molecular Segregation of Parkinsons Disease by Patient derived Neurons will also aim to identify and separate two major subtypes of PD those who experience tremors and those who do not to be able to better treat specific types of PD.

The National Institutes of Health estimates that up to 1 million people in the United States may have Parkinsons disease. Thats 1 million Americans with a difficult, progressive condition without a cure who must wait until their clinical symptoms are serious enough to be diagnosed, Higgins said. This federal investment to assist our Western New York researchers hopes to provide a path to earlier detection of Parkinsons to attempt treatment as quick as possible.

When we generated induced pluripotent stem cells from a group of Parkinsons disease patients and a group of normal subjects, we found that there were many significant differences in the expression levels of genes controlling the production, utilization and degradation of dopamine, Feng said. Thus, we want to investigate this further with the goal of developing a method for the objective diagnosis of Parkinsons disease. It might also allow us to predict years in advance who may develop Parkinsons.

Higgins has been an advocate for measures that advance Parkinsons research and treatment.Following meetings with the Michael J. Fox Foundation,the Parkinsons Foundation of WNY and local advocate and former congressman Jack Quinn, Higgins sent a letter to the Department of Veterans Affairs and the Department of Health and Human Services last January urging that access to boxing therapy in the treatment of Parkinsons be expanded, as well as more research be conducted to document the efficacy of the program.In February, he drafted a bipartisan letter supporting funding for a surveillance database at the Centers for Disease Control and Prevention to collect vital demographic information on people living with neurological diseases,a measure supported by the Michael J. Fox Foundation.

Go here to see the original:
Higgins announces $2.2 million grant to UB to support Parkinson's research - UB Now: News and views for UB faculty and staff - University at Buffalo...

Neurology Study: Contact Sports and Concussion in Rugby – LWOR – Last Word On Rugby

In a study that compared Rugby Players to Swimmers and Rowers, study author Ravi S. Menon, Ph.D., FRSC, of Western University in London, Canada, found that contact sports have a correlation with brain damage and concussion.

According to a new study published in the June 17, 2020, online issue of Neurology, the medical journal of theAmerican Academy of Neurology, the study compared rugby players to other female college athletes competing in the non-contact sports of swimming and rowing.

101 female college athletes took part in the study. This included 70 rugby players and 31 rowing or swimming athletes. The study followed a subset of the rugby players for at least two years. It also followed swimmers and rowers for one year.

In terms of rugby union, the fact that the tackler and the tackled player are at risk, is well established. What this study has found is that exposure at any level, can result in changes to a player [subject] microstructure of the white matter, including in nerve fibers that connect areas of the brain. This white matter controls basic emotions like fear, pleasure, and anger. In some of the rugby players, the changes progressed over time.

While any contact sport such as football, basketball, and American Football may result in injury. Rugby, with players intent to stop the forward progress of the opposition, putting bodies and especially heads, in a compromised position (in the contact area). These results indicate that only after a short term, affects can be found more in rugby union. More so than in non-contact sports.

Even with no concussions, the repetitive impacts experienced by the rugby players [even during training] clearly had effects on the brain, said Menon.

Researchers used magnetic resonance imaging (MRI) to scan the brains of all the athletes during in- and off-season play. With the brain scans, researchers examined how water molecules moved throughout the white matter. This was to determine if there were microstructural brain changes.

Researchers found differences in the functional organization of the brain too. When compared to swimmers and rowers, rugby players had changes in connectivity. How the brain communicates between the areas of the brain that control memory retrieval and visual processing.

While we only looked at these impacts during a few events during the season, previous research has shown these kinds of subclinical impacts may accumulate over years of participation in contact sports.

More research is needed to understand what these changes may mean and to what extent they reflect how the brain compensates for the injuries, repairs itself or degenerates so we can better understand the long-term health effects of playing a contact sport.

With growing evidence of new and established studies, many will conclude that the game is counter-productive. The risk is too large. Current players will, and continue to suffer from injury due to contact sports activity.

HIA tests today are risk-averse, to remove any player from harm. This head injury assessment can mean the difference between a serious injury and player welfare. Although, the results of the study by Western University prove that any exposure is harmful.

Head injury protocols have been issued by World Rugby. Players should aim to lower the tackle area. Promoting less impact that includes the head area should improve the welfare of players. Yet at the center of the argument is, that it is the choice of the individual.

In time, rule variations, reduced emphasis in the breakdown, changes to contact sports like rugby may alter the sport. But, the focus will and should focus on health and welfare first.

___________________________________

The study was supported by the Schulich School of Medicine & Dentistry at Western University, the Canadian Institutes for Health Research, Brain Canada, Canada First Research Excellence Fund, and the Natural Sciences and Engineering Research Council of Canada.

Main photo creditEmbed from Getty Images

More:
Neurology Study: Contact Sports and Concussion in Rugby - LWOR - Last Word On Rugby

icometrix named to the 2020 CB Insights Digital Health 150 – List of Most Innovative Digital Health Startups – PRNewswire

NEW YORK, Aug. 13, 2020 /PRNewswire/ --CB Insights today named icometrix to its second annual Digital Health 150 ranking, which showcases the 150 most promising private digital health companies in the world.

The 2020 Digital Health 150 cohort highlights startups that are reimagining the lines of the traditional healthcare experience across 12 categories, from Virtual Care Delivery and Clinical Trials, to Drug Discovery and Specialty Care.

"This year's Digital Health 150 is our most global ever, covering the best private healthcare companies from 17 countries. Beyond geographic diversity, these companies are innovating across the entire healthcare value chain, spanning technologies that benefit pharma & biotech companies, to payers, hospitals, insurers, and more," said CB Insights CEO Anand Sanwal.

"We are honored to receive this renewed recognition by CB Insights," said Wim Van Hecke, CEO of icometrix. "Innovative digital health solutions are changing healthcare at a rapid pace. Through our brain MRI and CT measures, we help radiologists, neurologists, neurosurgeons, and their referring physicians to make more informed and more accurate decisions for patients with neurological disorders. With our recently launched icompanion, a free app for people with multiple sclerosis to track symptoms, treatments, physician visits, as well as view their MRI scans on-the-go. All of this contributes to enhanced patient care worldwide, providing individual patients with the right treatment at the right moment," Van Hecke concludes.

icometrix offers AI solutions to obtain clinically meaningful data from MR and CT scans. Its icobrain portfolio incorporates brain volumetrics for patients with neurological conditions in clinical practice. icolung, an AI solution launched to help fight COVID-19, quantifies lung pathology on chest CT in admitted COVID-patients. Today, icometrix is internationally active in over 100 clinical practices and works with healthcare providers and pharmaceutical companies on the evaluation of drug trials for neurological diseases.

About icometrix icometrix (Leuven, Belgium; Chicago, USA) is the world leader in software solutions to obtain clinically meaningful data from brain MRI and CT scans. The fully automated icobrain software has market clearance in the USA, Europe, Japan, Canada, Brazil, India, and Australia. Today, the icobrain portfolio is used in patients with multiple sclerosis, dementia, and brain trauma.

Contact: Wim Van Hecke, CEO[emailprotected]+32 16-369-000icometrix.com

Press Kit:https://icometrix-files.s3-eu-west-1.amazonaws.com/Press-releases/Press-Kit-icometrix-20200813.zip

SOURCE icometrix

http://icometrix.com

Read the original:
icometrix named to the 2020 CB Insights Digital Health 150 - List of Most Innovative Digital Health Startups - PRNewswire

Interventional Neurology Device Market by Type, Application, Element Global Trends and Forecast to 2025 – 3rd Watch News

Market Study Report LLC has added a new report on Interventional Neurology Device Industry Market Size that provides a comprehensive review of this industry with respect to the driving forces influencing the industry. Comprising the current and future trends defining the dynamics of this industry vertical, this report also incorporates the regional landscape of Interventional Neurology Device Industry market in tandem with its competitive terrain.

The Interventional Neurology Device Industry market report is an in-depth analysis of this business space. The major trends that defines the Interventional Neurology Device Industry market over the analysis timeframe are stated in the report, along with additional pointers such as industry policies and regional industry layout. Also, the report elaborates on the impact of existing market trends on investors.

Request a sample Report of Interventional Neurology Device Industry Market at:https://www.marketstudyreport.com/request-a-sample/2728328

COVID-19, the disease it causes, surfaced in late 2020, and now had become a full-blown crisis worldwide. Over fifty key countries had declared a national emergency to combat coronavirus. With cases spreading, and the epicentre of the outbreak shifting to Europe, North America, India and Latin America, life in these regions has been upended the way it had been in Asia earlier in the developing crisis. As the coronavirus pandemic has worsened, the entertainment industry has been upended along with most every other facet of life. As experts work toward a better understanding, the world shudders in fear of the unknown, a worry that has rocked global financial markets, leading to daily volatility in the U.S. stock markets.

Other information included in the Interventional Neurology Device Industry market report is advantages and disadvantages of products offered by different industry players. The report enlists a summary of the competitive scenario as well as a granular assessment of downstream buyers and raw materials.

Revealing a gist of the competitive landscape of Interventional Neurology Device Industry market:

Ask for Discount on Interventional Neurology Device Industry Market Report at:https://www.marketstudyreport.com/check-for-discount/2728328

An outlook of the Interventional Neurology Device Industry market regional scope:

Additional takeaways from the Interventional Neurology Device Industry market report:

This report considers the below mentioned key questions:

Q.1. What are some of the most favorable, high-growth prospects for the global Interventional Neurology Device Industry market?

Q.2. Which products segments will grow at a faster rate throughout the forecast period and why?

Q.3. Which geography will grow at a faster rate and why?

Q.4. What are the major factors impacting market prospects? What are the driving factors, restraints, and challenges in this Interventional Neurology Device Industry market?

Q.5. What are the challenges and competitive threats to the market?

Q.6. What are the evolving trends in this Interventional Neurology Device Industry market and reasons behind their emergence?

Q.7. What are some of the changing customer demands in the Interventional Neurology Device Industry Industry market?

For More Details On this Report: https://www.marketstudyreport.com/reports/covid-19-outbreak-global-interventional-neurology-device-industry-market-report-development-trends-threats-opportunities-and-competitive-landscape-in-2020

Related Reports:

1. COVID-19 Outbreak-Global Testosterone Booster Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020Read More: https://www.marketstudyreport.com/reports/covid-19-outbreak-global-testosterone-booster-industry-market-report-development-trends-threats-opportunities-and-competitive-landscape-in-2020

2. COVID-19 Outbreak-Global Thin Film Drug Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020Read More: https://www.marketstudyreport.com/reports/covid-19-outbreak-global-thin-film-drug-industry-market-report-development-trends-threats-opportunities-and-competitive-landscape-in-2020

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

See the article here:
Interventional Neurology Device Market by Type, Application, Element Global Trends and Forecast to 2025 - 3rd Watch News

Accentuate the Positive: Appreciative Inquiry as a Tool for… : Neurology Today – LWW Journals

Article In Brief

One academic medical center has put into place a wellness program, based on the concept of appreciative inquiry, which asks neurology residents to explore their existing strengths and successes.

Christopher Traner, MD, a chief neurology resident at Yale School of Medicine, had become familiar with common approaches to combating physician and resident burnoutprograms aimed at building resiliency in individual clinicians, such as mindfulness coaching, and efforts to identify and combat the stress factors, like a massive firehose-worthy flow of medical data to manage, that lead to burnout.

But when his assistant program director, Jeffrey Dewey, MD, assistant professor of neurology, invited him to be a part of a group of eight residents to do hour-long face-to-face interviews on a strategy for burnout prevention called Appreciative Inquiry, Dr. Traner was intrigued. It sounded very different from anything I'd participated in before, he said.

Appreciative Inquiry (AI) is a strengths-based, positive approach to leadership development and organizational change. Instead of approaches like a SWOT (strengths, weaknesses, opportunities and threats) analysis, which spend significant time on pitfalls and problems, AI asks people to explore strengths and successes that already exist.

At its heart, AI is about the search for the best in people, their organizations, and the strengths-filled, opportunity-rich world around them, wrote David Cooperrider, PhD, a Distinguished University Professor at Case Western University and the originator of the concept, in a 2015 book on the appreciative inquiry process.

AI is not so much a shift in the methods and models of organizational change, but AI is a fundamental shift in the overall perspective taken throughout the entire change process to see the wholeness of the human system and to inquire into that system's strengths, possibilities, and successes.

Dr. Dewey can't remember where he first came across the concept of AI, but it immediately struck a chord with him. I've always been very interested in positive psychology and optimal human performance, so it really resonated with my world view, he said. He had also learned of a few academic medical centers that had applied AI across their institutions, including Indiana University School of Medicine and the University of Virginia Health System, which now has a Center on Appreciative Practice that has published a book on appreciative inquiry in health care.

So when he was selected to participate in the AAN's Live Well, Lead Well program, in which clinicians develop project-based initiatives for improving practice culture and reducing burnout, he decided it was the perfect opportunity to put AI into practice in the Yale neurology residency program.

The full AI process is a cycle of five Ds, including Definition, Discovery, Dream, Design, and Destiny/Delivery; Dr. Dewey focused his project on the discovery phase, which involves interviewing stakeholders in an organization about what is working well and gives life to the institution.

In the era of burnout, we know really well what isn't working, he said. It's easy to become focused on that and forget about the best of what we do. I wanted to understand what we were doing well and what helped the residents thrive, and to teach them this mode of thinkinghow to focus on what's going well around them.

In the pilot series of one-on-one interviews, Dr. Dewey spoke with Dr. Traner and seven other residents about how they found pleasure in their work and the things that motivated them to keep coming back. When in their residency did they feel at their absolute best? What circumstances led to those feelings?

One thing he asked me was, Tell me about a patient you recently cared for where you had a positive experience, Dr. Traner recalled. As I began talking about patients I had cared for and positive interactions with them and their families, I realized how easy it is for those things to get lost in the day to day minutiae of being at work, writing notes, and helping discharge patients. It's easy to lose focus on why you went into medicine in the first place.

For example, Dr. Traner, who will stay at Yale for an epilepsy fellowship after completing his residency, told Dr. Dewey about a patient who works maintaining and supplying swimming pools.

He was having trouble accessing care for his epilepsy because his work is so seasonal, and hospital admissions for epilepsy monitoring units are typically most open in the summer, Dr. Traner said. So I spent a lot of time working with him and eventually spoke to his boss and got a dispensation for him to take off work for an EMU admission. We were able to characterize his seizures and with medication adjustments, he's now been seizure-free for two years and it's really made all the difference in his life. This is one of the reasons I chose epilepsy as a subspecialty: people don't realize the toll a disease like that can take on someone, particularly with the social stigma. His positive experience is one that I always think about.

One surprising common theme that arose during these hour-long interviews, which were conducted under the auspices of an IRB-compliant study, was that of residents reporting some of their most positive experiences when pushed beyond their comfort zone.

To a person, they all reported feeling positive about going through a clinical experience that stressed themlike the first time they covered call overnightand being able to overcome that challenge, said Dr. Dewey.

For example, one resident described being early in their residency and doing a very intense emergency department shift where there were multiple stroke alerts and they felt like they were out of their element. But then later it hit them: I'm doing this. I'm a neurologist now. This goes with the positive psychology concept of eustress, stress that leads to growth. Most people were not necessarily enjoying themselves in the moment, but as they reflected on those experiences, they saw them as some of the best moments of their residency.

Almost all of these experiences involved situations in which the residents were required to act independently, with little or no supervision. This suggests that we should focus on setting our residents up for experiences in which they are highly challenged, and yet have the opportunity to grow, Dr. Dewey said. And then we need to give them the opportunity to reflect on those experiences in a structured way, because the reflection is just as important as the experience itself to the appreciative inquiry process. That could be done in the moment, immediately afterward, or at a later time. But it should not be just once a year or once in a residency. We are great at setting up regular opportunities for our residents to debrief critical incidents or bad outcomes with things like morbidity and mortality conferences, but not so great at doing the same with moments of success and growth.

After the eight one-on-one pilot interviews, Dr. Dewey assembled a larger focus group of all the neurology residents and paired them up to discuss what their ideal practice environment would look like, if there were no barriers.

We brainstormed all kinds of ideas, like protected time for case conferences where some other entity could take care of the patients so we could focus on our discussion and our learning, said Dr. Traner. No ideas were off limits. Then we talked about how to take baby steps toward some of those goals and making them achievable. Having a positive attitude about work and making people feel appreciated at work is so important. You don't want to distract people from what the problems are, but rather, address them in a positive way.

Jennifer Rose V. Molano, MD, FAAN, associate professor of neurology at the University of Cincinnati, FAAN, co-chair of the AAN's Wellness Joint Coordinating Council, and chair of the Live Well, Lead Well program said that Dr. Dewey's project was a natural fit, and could easily be replicated at other institutionsindeed, her department has already done so.

Our chair, Dr. Brett Kissela, really believes in the idea that we need to take care of ourselves so that we can take care of our patients, she said. At our last half-day retreat for about 200 members of our departmentfaculty, learners and administrative, clinical and research staffwe included two appreciative inquiry exercises focused on joy in work and high-functioning teams.

We had groups of ten per table, and each table had individual reflections followed by a table discussion, which they wrote up on a feedback sheet that was returned to leadership, Dr. Molano said.

What I like about AI is that it provides us with the opportunity to take a strength-based approach for growth within a group or department. Particularly in this time of tremendous change and uncertainty, it's important to use positive psychology techniques to figure out where our strengths are as we try to navigate this rapidly evolving new landscape.

Originally posted here:
Accentuate the Positive: Appreciative Inquiry as a Tool for... : Neurology Today - LWW Journals

Impel NeuroPharma Announces Primary Objectives Met In Pivotal Phase 3 Registration Study Of INP104 For The Treatment Of Acute Migraine – P&T Community

SEATTLE, June 10, 2020 /PRNewswire/ --Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) disorders with high unmet medical needs, today announced positive results from "STOP 301" (Safety and Tolerability of POD-DHE), the Company's pivotal Phase 3, open-label study of the safety and tolerability of INP104 (dihydroergotamine mesylate) or DHE, administered to the vascular rich upper nasal space via Impel's proprietary POD technology, for the treatment of acute migraine. The study, which treated over 5,650 migraine attacks, evaluated self-administered, intermittent use of INP104 for up to 52-weeks, and also collected in a diary exploratory efficacy data of INP104 as assessed by patient reported change from baseline in migraine measures during the course of the study.

Results showed the STOP-301 study met its primary objectives, with no new safety signals or concerning trends in nasal safety findings observed for INP104 following delivery of DHE to the upper nasal space. DHE is a molecule long relied upon for its high response rate and sustained efficacy. Its use has been limited in part by its availability only as an invasive injectable or in other delivery forms with high dosing variability. In the study, the majority of treatment-related adverse events for the 24-week Full Safety Set (FSS) (n=354) were mild and transient in nature. The most frequently reported adverse events (5%) during the entire 24-week period were nasal congestion (15.0%), nausea (6.8%), nasal discomfort (5.1%) and unpleasant taste (5.1%). The majority of patients (74% and 90%) completed the 24- and 52-week phases of the study, respectively. No drug-related serious adverse events (SAEs) were observed over the entire 52-week study.

"Despite historically being known as a highly effective treatment, use of DHE in the treatment of acute migraine has been limited due to dose-related side effects, inadequate or inconvenient routes of administration and high variability in dose delivered, making these data highly encouraging for clinicians who need an at-home option that also has the benefit of broad neurogenic activity," said Stewart J. Tepper, M.D., Professor of Neurology at the Geisel School of Medicine at Dartmouth and Director of the Dartmouth Headache Center in the Department of Neurology of Dartmouth-Hitchcock Medical Center. "Interestingly, an increased recognition of the link between migraine and gastrointestinal issues may be why nearly 60 and 90 percent of patients with migraine experience vomiting and nausea, respectively, during an attack which presents limitations for the use of oral therapies. If approved, INP104 has the potential to offer patients a non-oral alternative with an all-in-one approach to treating the whole migraine due to DHE's broad receptor binding profile.i"

In the study, INP104 delivered 1.45 mg of DHE, less than 72.5% of the currently approved dose (2.0 mg). Optimal dosing is critical so that patients may stand to benefit from the established efficacy profile of DHE, without the potentially triggering undesired side effects that can be experienced with delivering higher doses of drug to the lower nasal space. Per the approved product label for Migranal, the U.S. Food & Drug Administration (FDA) currently limits the maximum dose of DHE to 6.0 mg a week.

Exploratory efficacy data in the FSS (n=354) observed that 66.3% of patients achieved pain relief and 38% of patients achieved pain freedom at two hours following their first dose of INP104. In the Primary Safety Set (PSS) (n=185), 33.1% of patients who took an average of two or more treatments with INP104 per the 28-day period during the 24-week treatment phase, achieved pain freedom at two hours. Initial onset of pain relief began as early as 15 minutes for 16.3% of patients, which continued to improve over time. Additionally, sustained pain freedom was observed in the majority of patients, with 98.4% and 95% of patients reporting no recurrence of their migraine or use of rescue medications during the 24- and 48-hour periods after using INP104 during weeks 21-24. Together, these results suggest that upper nasal delivery may provide an effective, consistent, and well-tolerated alternative to acute oral and injectable treatments for migraine, while potentially providing the reliable efficacy, speed, and potency of the long-established DHE molecule without the need for an injection.

"We believe that these data add to the growing body of clinical evidence supporting the potential of INP104 to be a transformative new therapy for acute migraine. In addition to the STOP 301 study demonstrating INP104's potential to be both safe and well-tolerated when delivered to the upper nasal space, the data showed unsurpassed and sustained patient-reported pain freedom and pain relief rates compared to the best usual care in our exploratory efficacy analyses," said Stephen B. Shrewsbury, M.D., Chief Medical Officer of Impel NeuroPharma. "We believe the low incidence and mild nature of treatment-related adverse events are attributable to INP104's ability to reliably and consistently deliver an optimal low dose of DHE, which may enable patients to benefit from the established efficacy of this trusted molecule, without undesired side effects that may be experienced with higher doses of drug."

Further analysis of STOP 301 data is ongoing and will be submitted for future publication or presentation. Impel NeuroPharma plans to submit a New Drug Application to the FDA in the second half of 2020.

About STOP 301:The Phase 3 STOP 301 study enrolled 360 patients at 36 sites in the United States who had a documented diagnosis of migraine with or without aura, with at least two attacks per month for the previous six months. 354 patients received at least one dose of INP104 and comprised the Full Safety Set. 185 patients who took an average of two or more treatments with INP104 per 28-day period during the 24-week treatment period comprised the Primary Safety Set. Of those enrolled, 74% (n=262) of patients completed the 24-week treatment period. Reasons for treatment discontinuation included withdrawal by subject (n=25 [7.1%]), AEs (n=24 [6.8%]), lack of efficacy (n=21 [5.9%]), lost to follow-up (n=11 [3.1%]), non-compliance/protocol violation (n=5 [1.4%]), and physician's decision (n=1 [0.3%]). A subset of 73 patients continued into a 28-week treatment extension period to 52 weeks total, of which 90% completed.

About INP104:Impel NeuroPharma is currently developing INP104 with the goal to be a transformative new therapy for acute migraine. INP104 aims to optimize dihydroergotamine mesylate (DHE) for fast and lasting whole migraine relief, regardless of when in the migraine attack it is administered, without an injection. Importantly, INP104 is designed to deliver a lower dose of dihydroergotamine mesylate (DHE) compared to FDA-approved and investigational products in development via the nose. This may enable patients to benefit from the established efficacy of DHE, without the undesired side effects that may be experienced with delivery to the lower nasal space.

INP104 utilizes Impel's propellant-enabled POD technology to conveniently and consistently deliver optimal doses of DHE deep into the vascular rich upper nasal space, an ideal target for efficient drug administration, particularly for the majority of patients with migraine who experience nausea and/or vomiting during an attack, which presents limitations for the use of oral therapies, including triptans, CGRP inhibitors and ditans as well as other non-specific acute migraine medications.

About Acute Migraine:Migraine is a common and debilitating neurological disease characterized by recurrent episodes of severe head pain and associated with nausea, vomiting and sensitivity to light and sound.iiMigraine affects approximately 39 million people intheUnited States.iii Of the approximately 19 million diagnosed migraine patients, only four million are on prescription treatment.iv While triptans account for almost 70 percent of migraine therapies, approximately 30 to 40 percent of patients do not respond adequately to triptans and up to 79 percent of the patients who do respond to triptans report being dissatisfied with their current treatment and willing to try a new therapy.v

Further, evidence suggests that gastroparesis, delayed emptying of the stomach, is a prevalent feature in migraine that may delay or reduce the absorption of oral medications, including triptans, gepants and ditans. This means that acute medications can remain in the stomach for hours, delaying symptom relief, leading to loss of confidence (about future administration) and prolonged suffering for the current migraine attack.vi

About Impel NeuroPharma:Impel NeuroPharma, Inc. is a privately held, Seattle-based biopharmaceutical company focused on developing transformative therapies for people living with central nervous system (CNS) disorders with high unmet medical needs.The Company is rapidly advancing a late-stage product pipeline that optimizes the effectiveness of proven treatments for neurological conditions, including INP-104 for acute migraine, INP-107 for OFF episodes in Parkinson's disease, and INP-105 for acute agitation associated with schizophrenia, bipolar I disorder and autism.

IMPEL, POD and the IMPEL Logo are registered trademarks of Impel NeuroPharma, Inc. To learn more about Impel NeuroPharma, please visit our website athttp://impelnp.com.

About Precision Olfactory Delivery or POD TechnologyImpel's proprietary Precision Olfactory Delivery (POD) technology is able to deliver a range of therapeutic molecules and formulations into the vascular rich upper nasal space, believed to be a gateway for unlocking the previously unrealized full potential of these molecules. By delivering predictable doses of drug directly to the upper nasal space, Impel's precision performance technology enables increased and consistent absorption of drug, overriding the high variability associated with other nasal delivery systems.

While an ideal target for drug administration, to date no technology has been able to consistently deliver drugs to the upper nasal space. By utilizing this route of administration, Impel NeuroPharma has been able to demonstrate blood concentration levels for its investigational therapies that are comparable to intramuscular (IM) administration and can even reach intravenous (IV)-like systemic levels quickly, which could transform the treatment landscape for CNS disorders.

Importantly, the POD technology offers propellant-enabled delivery of dry powder and liquid formulations that eliminates the need for coordination of breathing, allowing for self- or caregiver-administration in a manner that may improve patient outcome, comfort, and potentially, compliance.

Migranal is a registered trademark of Bausch Health Companies Inc. or its affiliates.

Contact:Melyssa WeibleElixir Health Public RelationsPhone: (1) 201-723-5805Email: mweible@elixirhealthpr.com

iSilberstein SB. Headache. 2003; 43:144-166; Buzzi MG & Moskowitz MA. Cephalalgia. 1991; 11:165-168; Silberstein SD et al. Headache. 2020; 60:40-57; Migranal Product Information. Available at: https://www.bauschhealth.com/Portals/25/Pdf/PI/Migranal-PI.pdf. Accessed Jan 20, 2020.iiMayo Clinic. Migraine Symptoms & Causes. Last Accessed February 3, 2020.iiiMigraine Research Foundation. Migraine Facts. Last Accessed February 3, 2020.ivData on filevData on fileviAurora S, et al. Cephalalgia. 2013; 33:408-415; Tokola RA et al. Br J Clin Pharmacol. 1984. 18:867-871; Volans GN. Clin Pharmacokinet. 1978 3:313-318

View original content to download multimedia:http://www.prnewswire.com/news-releases/impel-neuropharma-announces-primary-objectives-met-in-pivotal-phase-3-registration-study-of-inp104-for-the-treatment-of-acute-migraine-301073558.html

SOURCE Impel NeuroPharma

Link:
Impel NeuroPharma Announces Primary Objectives Met In Pivotal Phase 3 Registration Study Of INP104 For The Treatment Of Acute Migraine - P&T Community